Interaction of Muscarinic Acetylcholine and N-Methyl-D-Aspartate \u2013Type Glutamate Receptors in the Regulation of Spatial Learning and Memory (Kolinergisten muskariini- ja glutamatergisten N-metyyli-D-Aspartaattireseptorien yhteisvaikutus paikkaoppimisen ja -muistin säätelyssä) by Aura, Juhana
KUOPION YLIOPISTO
UNIVERSITY OF KUOPIO
DEPARTMENT OF NEUROLOGY SERIES OF REPORTS NO 67, 2003
JUHANA AURA
INTERACTION OF MUSCARINIC ACETYLCHOLINE AND N-
METHYL-D-ASPARTATE -TYPE GLUTAMATE RECEPTORS IN THE
REGULATION OF SPATIAL LEARNING AND MEMORY
Doctoral dissertation
To be presented with assent of the Medical Faculty of the University of Kuopio for public
examination in Auditorium L1, canthia building of the university of Kuopio,
on Saturday 10th May 2003, at 12 noon
Department of Neuroscience and Neurology, University of Kuopio
Department of Neurology, Kuopio University Hospital
Distributor: Department of Neurology
University of Kuopio
P.O. Box 1627,
FIN-70211 Kuopio,
FINLAND
Tel. +358 17 162 689
Fax +358 17 162 048
Author’s address: Department of Neuroscience and Neurology
University of Kuopio
P.O. Box 1627,
FIN-70211 Kuopio
FINLAND
Tel. +358 17 162 014,
Fax. +358 17 162 048
Supervisors: Docent Heikki Tanila, M.D., Ph.D.
Department of Neuroscience and Neurology
University of Kuopio
Kuopio University Hospital
Dr. Sirja Ruotsalainen, Ph.D.
Department of Social Pharmacy
University of Kuopio
Reviewers: Professor Esa R. Korpi
Institute of Biomedicine
Pharmacology
University of Helsinki
FINLAND
Professor John K. Robinson, Ph.D.
Department of Psychology
State University of New York at Stony Brook
N.Y., USA.
Opponent: Dr. Paul Dudchenko, Ph.D.
Department of Psychology
University of Stirling
SCOTLAND, UK
ISBN  951-781-759-2
ISSN  0357-6043
Kuopio University Printing Office
Kuopio 2003
Finland
AURA, JUHANA. Interaction of muscarinic and N-methyl-D-aspartate -type glutamate receptors in the
regulation of spatial learning and memory. Series of Reports, No 67, Department of Neurology, University of
Kuopio 2003, 99 p.
ISBN  951-781-759-2
ISSN  0357-6043
ABSTRACT
Degeneration of cholinergic cells in the basal forebrain correlates with the cognitive impairment seen
in Alzheimer’s disease (AD), but so far the cognitive improvement of AD patients receiving
cholinergic therapy has only been modest at best. In addition, degeneration of glutamate-containing
cells has been observed in AD, thus suggesting that dysfunction of glutamatergic receptors may
contribute to the cognitive decline of AD patients. The aim of this study was to investigate the role and
possible interaction of the cholinergic system and N-methyl-D-aspartate (NMDA) glutamate receptors
in the regulation of working memory and spatial navigation in rats. The role of muscarinic and NMDA
receptors in the regulation of spatial working memory was studied using the delayed non-matching to
position (DNMTP) task and intracerebroventricular administration of the muscarinic receptor
antagonists scopolamine, pirenzepine and methoctramine, as well as the NMDA receptor antagonist
CPP. The contribution of cholinergic system and NMDA receptors to age-related deficit in spatial
navigation was assessed using the Morris water maze task and intraperitoneal administration of D-
cycloserine and tetrahydroaminoacridine. The main results were the following. 1) Blockade of
muscarinic receptors in the central nervous system with scopolamine and pirenzepine delay-
independently disrupted DNMTP performance, suggesting a non-mnemonic effect on performance.
Selective blockade of M2 receptors with methoctramine delay-dependently improved performance in
the DNMTP task, suggesting a specific, although modest improvement of working memory at long
delays. 2) Blockade of central NMDA receptors with CPP resulted in a delay-independent defect,
while combined administration of subthreshold doses of CPP and scopolamine disrupted only non-
mnemonic task parameters (motor activity, attention or motivation). Combined CPP and pirenzepine
administration at subthreshold doses had no effect on DNMTP task performance. These results suggest
that combined blockade of central non-M1 receptors and NMDA receptors disrupts non-mnemonic
aspects of DNMTP performance. 3) In the prefrontal cortex, CPP dose-dependently disrupted
maintenance of working memory, whereas scopolamine disrupted only non-mnemonic parameters. 4)
D-cycloserine and tetrahydroaminoacridine alleviated age-related deficit in spatial navigation when
administered either separately or in combination with subthreshold doses. 5) However, the alleviating
effect of both D-cycloserine and tetrahydroaminoacridine (separately or in combination) disappeared
after pre-training under different conditions, including pre-training for non-spatial escape strategies. In
contrast, the age-related spatial navigation defect still remained after the pre-training procedures.
These results suggest that tetrahydroaminoacridine and D-cycloserine  do not themselves alleviate age-
related spatial memory deficit, but may enhance procedural aspects of water maze learning in aged
rats. CONCLUSION: Although the conjoint modulation of muscarinic and NMDA receptors most
likely has no direct effect on memory functions, the indirect stimulating effects on attention, arousal
and motivation might help alleviate cognitive impairment in AD patients.
National Library of Medicine Classification: WT155, WT104, QV77, QV126, WM173.7
Medical Subject Heading:  Alzheimer disease; aged; cholinergic agents; N-methylaspartate; receptors,
cholinergic; muscarinic antagonists; learning;  memory; memory, short-term;  drug therapy; rats;
cognition; drug interactions;   spatial behavior
      This book is dedicated to Annamari and Konrad
ACKNOWLEDGEMENTS
This study was performed in the Department of Neuroscience and Neurology at the
University of Kuopio during years 1995-2003.
I thank my supervisors, Docent Heikki Tanila, Dr. Sirja Ruotsalainen and Docent Paavo
Riekkinen Jr for their teaching and supervision.
I thank Professor Esa Korpi and Professor John Robinson, the official reviewers of this thesis,
for their constructive criticism and suggestions for improving the manuscript.
I also express my gratitude to Professor Hilkka Soininen, Docent Riitta Miettinen, Docent
Thomas van Groen, Professor Aarne Ylinen, Docent Jouni Sirviö, Professor Irina Alafuzoff,
Professor Tuula Pirttilä and Professor Juhani Sivenius for their excellent teaching in
neuroscience.
I want to thank Anna-Lisa Gidlund for her first rate technical assistance and Esa Koivisto and
Sari Palviainen for their signifcant help during these years. I also want to thank Nilla
Karjalainen, Mari Tikkanen, Tuija Parsons and  Hanna Turkki  for their help. I am also
grateful to the personnel of National Laboratory Animal Centre of the University of Kuopio.
I thank Ken Pennington and Ewen MacDonald for revising the language of the manuscripts.
I also wish to thank Arturo Garcia-Horsman for his help with binding properties of
muscarinic receptor antagonists and Pirjo Halonen for her assistance with biostatistical
problems.
My deepest and warmest thanks to Markus Björklund, Taneli Heikkinen, Mikko Hiltunen,
Jouni Ihalainen, Sami Ikonen, Pekka Jäkälä, Giedrius Kalesnykas, Petri Kerokoski, Petri
Kolehmainen, Erkki Kuusisto, Mia Mikkonen, Jukka Puoliväli, Maaria Roschier, Pekka
Santtila, Victor Solovyan,  Tero Tapiola, and Iain Wilson for their friendship. I also want to
thank Irina Gurevicine, Kestutis Gurevicius, Anne Hämäläinen,  Inga Kadish, Miia Kivipelto,
Pauliina Korhonen, Minna Korolainen, Jani Kuitunen, Sergiy Kyrylenko, Li Liu, Laura
Parkkinen, Maija Pihlajamäki, Mia Pirskanen, Mati Reeben, Anna Rissanen, Minna
Riekkinen, Raimo Pussinen and Jun Wang for their friendly collaboration.
I also wish to thank all the members of our sähly (floor-ball) team and my Krav Maga training
partners for many relaxing moments with hard physical exercise. I also want to thank Juuso
Kallinen, Juha Kauppi and  Tsegayesus Kiflie Beka for their warm friendship during the past
years.
I thank my parents Kirsti Kokko and Erkki Aura, and my sisters Johanna and Jenni and my
brother Tero.
My dearest thanks to my wife Annamari for her love and encouragement and my son Konrad
for his smile and showing me what is really important in life.
This study was financially supported by the University of Kuopio and the Kuopio University
Foundation, the Finnish Cultural Foundation of Northern Savo and the Finnish Medical
Society.
Kuopio, May 2003
Juhana Aura
ABBREVIATIONS
ACh acetylcholine
AChE acetylcholinesterase
AD Alzheimer’s disease
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid
ANOVA analysis of variance
ChAT choline acetyltransferase
CNS central nervous system
CPP (+/-)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
DCD delayed conditional discrimination task
DCS D-cycloserine
dmPFC dorsomedial prefrontal cortex
dlFC dorsolateral frontal cortex
DMTP delayed matching to position
DNMTP delayed non-matching to position
HC hippocampus
i.c. intracerebral
i.c.v. intracerebroventricular
LTP long-term potentiation
M1-5 muscarinic acetylcholine receptor subtypes 1-5
MS medial septal nucleus
NMDA N-methyl-D-aspartate
NBM nucleus basalis of Meynert
NR1-2 NMDA receptor subunits 1-2
PFC prefrontal cortex
SPSS/PC+ statistical package for social sciences/personal computer
THA tetrahydroaminoacridine (tacrine)
LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following original publications that are referred to in the text by
the Roman numerals I-V.89
I Aura J, Sirviö J, Riekkinen P Jr. Methoctramine moderately improves memory but
pirenzepine disrupts performance in delayed non-matching to position test. Eur. J.
Pharmacol, 333:129-134, 1997.
II Aura J, Riekkinen P Jr. Blockade of N-methyl-D-aspartate and muscarinic receptors jointly
disrupts performance in delayed non-matching to position task. Submitted.
III Aura J, Riekkinen P Jr. Blockade of NMDA receptors located at the dorsomedial
prefrontal cortex impairs spatial working memory in rats. Neuroreport, 10:243-248, 1999.
IV Aura J, Riekkinen M, Riekkinen P Jr. Tetrahydroaminoacridine and D-cycloserine
stimulate acquisition of water-maze spatial navigation in rats. Eur. J. Pharmacol, 342:15-20,
1998.
V Aura J and Riekkinen P Jr. Pre-training blocks the improving effect of
tetrahydroaminoacridine and D-cycloserine on spatial navigation performance in aged rats.
Eur J Pharmacol. 390: 313, 2000.
CONTENTS
1. INTRODUCTION........................................................................................................................................... 15
2. REVIEW OF THE LITERATURE............................................................................................................... 17
2.1 CLASSIFICATION OF MEMORY...................................................................................................................... 17
2.2 MUSCARINIC RECEPTORS ............................................................................................................................ 23
2.2.1 Introduction: Brain cholinergic system.............................................................................................. 23
2.2.2 Signal transduction and localization.................................................................................................. 24
2.2.3 Cognitive functions mediated by muscarinic receptors...................................................................... 27
2.2.4 Muscarinic receptors in aging and AD .............................................................................................. 30
2.3 N-METHYL-D-ASPARTATE (NMDA) RECEPTORS ........................................................................................ 33
2.3.1 Introduction: glutamatergic receptors ............................................................................................... 33
2.3.2 NMDA receptor structure and signal transduction............................................................................ 34
2.3.3 Behavioural functions mediated by NMDA receptors ........................................................................ 36
2.3.4 NMDA receptors in aging and AD ..................................................................................................... 38
2.4 INTERACTION BETWEEN MUSCARINIC AND NMDA RECEPTORS IN LEARNING AND MEMORY FUNCTIONS.... 39
3. AIMS OF THE STUDY.................................................................................................................................. 41
4. MATERIALS AND METHODS ................................................................................................................... 42
4.1 ANIMALS..................................................................................................................................................... 42
4.2 IMPLANTATION OF INFUSION CANNULAS ..................................................................................................... 42
4.3 PHARMACOLOGICAL AGENTS ...................................................................................................................... 43
4.4 BEHAVIOUR ................................................................................................................................................ 45
4.4.1 Delayed non-matching to position task (DNMTP) (I - III)................................................................. 45
4.4.2 Morris water maze (IV and V)............................................................................................................ 48
4.5 HISTOLOGY................................................................................................................................................. 52
4.6 STATISTICS.................................................................................................................................................. 52
5. RESULTS ........................................................................................................................................................ 53
5.1 DNMTP TASK ............................................................................................................................................ 53
5.1.2 The effects of combined i.c.v. administration of scopolamine, pirenzepine and CPP on DNMTP
task performance (Publications I and II). ......................................................................................... 55
5.1.3 The effects of CPP and scopolamine (i.c.) on DNMTP task performance in dmPFC or dlFC (III)... 56
5.1.3 Histology ............................................................................................................................................ 59
5.2 WATERMAZE TASKS.................................................................................................................................... 59
5.2.1 The effects THA and DCS (i.p.) on spatial navigation of aged rats ( IV)........................................... 59
5.2.2 The effects of pre-training on the improved spatial navigation of aged rats induced by
THA and DCS (V).............................................................................................................................. 61
6. DISCUSSION .................................................................................................................................................. 64
6.1 METHODOLOGICAL CONSIDERATIONS ......................................................................................................... 64
6.1.1 DNMTP task. ...................................................................................................................................... 64
6.1.2 Water maze task.................................................................................................................................. 67
6.2 SPATIAL WORKING MEMORY ....................................................................................................................... 68
6.2.1 The effect of centrally administered muscarinic antagonists is not specific for working memory..... 68
6.2.3 Combined central administration of CPP and either scopolamine or pirenzepine has no specific
 effect on working memory. ............................................................................................................... 72
6.2.4 Local microinfusion of the NMDA antagonist CPP in the PFC disrupted working memory
dose-dependently............................................................................................................................... 74
6.2.5 Local administration of muscarinic antagonist scopolamine in the PFC disrupted non-mnemonic
 parametres in the DNMTP task........................................................................................................ 75
6.3 SPATIAL LEARNING AND MEMORY............................................................................................................... 77
6.3.1 Aging and spatial navigation ............................................................................................................. 77
6.3.2 Combined administration of THA and DCS at sub-effective doses improves water maze learning
in aged rats, but the improving effect disappears after pre-training. ............................................... 78
7. CONCLUSIONS ............................................................................................................................................. 81
REFERENCES.................................................................................................................................................... 82
APPENDIX: ORIGINAL PUBLICATIONS (I-V) ........................................................................................ 100
15
1. INTRODUCTION
Alzheimer's disease (AD) is the leading cause of dementia, accounting for approximately 50%
of all dementias in western countries (Francis et al., 1999). The first symptoms of AD include
difficulties in learning new information and impairment of recent memory (Kaye, 1998).
Typical pathological changes in AD are beta amyloid plaques, neurofibrillary tangle
formation and loss of cholinergic cells in the basal forebrain. Cholinergic cell death has been
the basis for the cholinergic hypothesis of AD and the development of the first AD drugs, the
acetylcholinesterase (AChE) inhibitors (Bartus et al., 1982). AChE inhibitors decrease the
cleavage of acetylcholine (ACh) in the synaptic cleft, thus enhancing the compromised
cholinergic function in AD. During the design of the studies presented in this thesis, the
AChE inhibitor tetrahydroaminoacridine (tacrine) was the only drug available for relieving
the symptoms of AD. Today, three other AChE inhibitors, donepezil, rivastigmine and
galantamine, are in clinical use. These new AChE inhibitors are well tolerated and have
proved to be safer than tacrine, which is liver toxic in humans. However, the cognition
enhancing effect of even the new AChE inhibitors is modest at best, clearly underscoring the
urgent need for developing new treatments for AD.
The pathogenesis of AD is complex and involves several different biochemical pathways. In
addition to disrupted cholinergic function, a loss of glutamatergic terminals in neocortical
areas and the hippocampus is seen in AD (Francis et al., 1999). Moreover, the number of
NMDA receptors decreases over the course of the disease, suggesting that decreased NMDA
receptor function may be related to the symptoms of AD (Wang et al., 2000; Young, 1987).
On the other hand, it has been suggested that that NMDA receptor-mediated Ca2+ toxicity
may contribute to nerve cell degeneration in the cortex and hippocampus, thus implicating
increased NMDA receptor activity as one possible cause for neuronal cell death in AD
(Maragos et al., 1987). It appears that the NMDA receptor is a Janus-faced mediator with
complex mechanisms involved in AD pathology and symptoms.
As in AD, defects in NMDA receptor-mediated neurotransmission as well as dysfunction of
the brain cholinergic system occur during aging, especially in laboratory rodents (Amenta et
al., 1995; Michalek et al., 1990; Mitchell and Anderson, 1998; Tamaru et al., 1991). In
addition, aged rats show a spatial learning deficit in the Morris water maze task which has
been linked to dysfunction of the hippocampus and the septo-hippocampal pathway
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(Gallagher and Nicolle, 1993; Nilsson and Gage, 1993). Because of this link between
dysfunctional hippocampus and spatial learning deficit, aged rats have been used to model the
memory impairment occurring in AD (Riekkinen et al., 1998). In rodents, performance in
operant-delayed working memory tasks has also been linked to proper functioning of the
hippocampus, a brain structure that is damaged early in AD (Aggleton, 1992; Dunnett, 1985;
Dunnett et al., 1990; Maruki et al., 2001). In addition to the hippocampus, the performance of
rodents in delayed tasks depends on the function of the prefrontal cortex, a structure known to
be important for the regulation of working memory and attentional control of behaviour
(Dunnett, 1990; Dunnett et al., 1990).
Recently, a new drug has been introduced for the treatment of AD. The NMDA antagonist
memantine has been used for over ten years in Germany as a neuroprotective agent, and is
now gaining acceptance throughout the world. Thus far, the beneficial effects have been
modest, as with the cholinesterace inhibitors; however, it is only a matter of time until studies
with combined administration begin to bear fruit. Although the motivation for treating AD
symptoms with memantine is based on an approach different from our model, possible
interactions between the cholinergic system and the NMDA receptors are more interesting
today than ever before. A possible benefit resulting from combined medication is the use of
smaller drug doses with probably fewer side effects. For future drug development, a growing
amount of studies are needed aimed at examining the interaction of NMDA receptors and the
cholinergic system in animal models.
In the present series of studies, we aimed to examine the interaction between cholinergic and
NMDA receptor medication. Firstly, we studied whether separate or combined blockade of
brain NMDA and muscarinic receptors induces working memory deficit in the delayed non-
matching to position task. This task is also capable of monitoring whether non-mnemonic
aspects of performance, such as sensorimotor disturbance or attentional dysfunction,
contribute to behavioral changes. We focused this study on the prefrontal cortex, which is the
brain structure most closely implicated in spatial working memory. Secondly, we studied
whether conjoint stimulation of cholinergic system and NMDA receptors attenuates an age-
related spatial navigation deficit in rats undergoing the Morris water maze task. We also used
a modification of the task, in which pre-training of the rats helped them to acquire the basic
skills needed in this task, thus enhancing the task specificity for testing the spatial aspects of
17
navigation behaviour.
2. REVIEW OF THE LITERATURE
2.1 Classification of memory
Fig. 1. Classification of memory (adapted from (Squire et al., 1993)).
Memory can be defined as the process by which we can retain newly acquired information
over time. The formation of memory “engram”, a representation of memory in the brain, is a
process of time-dependent consolidation (McGaugh, 2000). Based on the time period that
information can be sustained, memory can be divided into three basic types or stages:
sensory, short-term and long-term memory (Woolf, 1997). The incoming information is first
held in very brief sensory storage, either in visual sensory memory (iconic memory) or
auditory sensory memory (echoic memory). Most of the information in sensory memory is
lost within a fraction of second, thus enabling only a small portion of information to be
transmitted into short-term memory. The processing of incoming sensory information takes
place in the cortical areas that are responsible for the initial perception of sensory stimuli, i.e.
in the primary auditory and visual cortices (Woolf, 1997).
The second stage, short-term memory, is responsible for acquisition and conscious processing
of the information to be later transmitted into either long-term memory storage or
subsequently forgotten (Squire et al., 1993; Willingham, 1997). The time period during which
short-term memory is responsible for maintaining information is elastic, varying from seconds
habituation
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to 10 - 20 minutes, depending on the type of information and task used to assess memory
(Glassman, 1999). In animal research, the term working memory is often used as a synonym
for short-term memory. The definition of working memory varies depending on the animal
species, task used and corresponding researcher. For example, professor Patricia Goldman-
Rakic has used delayed response tasks for monkeys that “tap working memory processes
because the animal must retain the memory of the location of the stimulus during the period
of a delay” (Goldman-Rakic, 1992). In delayed response tasks, the delay is normally from 5 to
60 s. Professor David Olton, the developer of the radial arm maze task for rats, defines
working memory as a procedure where “stimulus information is useful for one trial of an
experiment, but not for subsequent trials” (Olton et al., 1979). In Oltons task, the delay is
from 30 s to 2 h. Since the definitions vary, it is very important to know which definition of
working memory and which task is used for a particular study; otherwise the reader’s
interpretation of the results may be misleading (table 1).
In human psychology, short-term memory can also been seen as a system that provides
temporary storage, maintenance and controlled manipulation of the information necessary for
complex cognitive tasks, such as language comprehension, reasoning and spatial ability
(Baddeley, 1992; Wagner, 1999). This concept often uses the term working memory instead
of short-term memory. Human working memory is not considered to be a single unitary
system but consists of three independent subsystems. The central executive system is
concerned with the attentional control of behaviour and coordinating the function of two slave
systems: the phonological loop (verbal tasks) and the visuospatial "sketch pad" (visual tasks)
(Baddeley, 1992). Typical features of human working memory are the capability to keep
information “on-line” over a delay period (Willingham, 1997), and attention span (digit span),
i.e. the capacity to handle the average of seven individual items simultaneously in working
memory (Glassman, 1999; Miller, 1956).
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Table 1. Widely used rodent tasks to evaluate short-term/working memory and long-term
memory.
SHORT-TERM MEMORY
 memory span reinforcement
D(N)MTP
- operant box 1-30 s positive
- T-maze, Y-maze 10 - 120 s positive
DELAYED ALTERNATION
- T-maze, Y-maze 10 - 120 s positive
SPONTANEOUS ALTERNATION
- T-maze, Y-maze 1 - 120 s no (=
spontaneous)
RADIAL ARM MAZE (all arms baited) 1 - 30 min positive
WATER MAZE (working memory
version)
1 - 5 min negative
3-PANEL RUNWAY 2 min positive
HOLE BOARD 1 – 5 min no
LONG-TERM MEMORY
memory span reinforcement
PASSIVE AVOIDANCE 24h - days negative
CONTEXT
CONDITIONING
24h - days negative
WATER MAZE 1min – days negative
RADIAL ARM MAZE
(3-4/ 8 arms baited)
1min – days positive
HOLE BOARD 1min – days positive
POSITION
DISCRIMINATION
 (T-maze)
1min – days positive/negative
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The third stage of memory, long-term memory, can be divided into two forms: explicit
(declarative, relational) and implicit (non-declarative, procedural) memory (Squire et al.,
1993; Willingham, 1997). Explicit memory allows us to consciously remember facts and
events from the past, and to learn new information of when and where something has
happened, and what that something is. When people are talking about memory in general,
they usually mean explicit memory that is related to everyday experiences and associated with
things that we are aware of. Explicit memory can be further divided into episodic and
semantic memory (Willingham, 1997). Episodic memory allows us to learn new information
of when and where something has happened, i.e. the memories of experiences associated with
a particular time and place. Semantic memory, on the other hand, allows us to learn what
something is, i.e. the memories that are associated with general knowledge of things and
facts. The other form of long-term memory, implicit memory, is associated with the learning
of skills and habits (Squire et al., 1993; Willingham, 1997). Implicit memories cannot be
brought to mind as conscious awareness of what is being remembered. Typically, an implicit
memory is formed through repeated practice, and once the memory is acquired, it is resistant
to forgetting. The classification of implicit memory also includes classical conditioning,
emotional conditioning, and a phenomenon called priming (Willingham, 1997). Priming can
be defined as “an improved facility for detecting or identifying perceptual stimuli on recent
experience with them” (Squire et al., 1993).
The division between explicit and implicit memory is based on findings from patients with
damage in the medial temporal lobe structures, particularly the hippocampus (HC), entorhinal
and perirhinal cortex, and the diencephalon (Willingham, 1997). One of these patients known
by his initials, H.M., is probably the most famous patient in the history of neuroscience.
These patients fail to learn new information and to recall or recognise it even a few minutes
later. In addition to anterograde amnesia, these patients also have a retrograde amnesia for up
to 10 years. Since these patients have intact working memory and implicit memory
(conditioning, priming and learning of motor skills), these types of memory have to be
processed in other brain areas than the medial temporal lobe (Willingham, 1997). The medial
temporal lobe structures are also responsible for a special kind of memory processing in
animals. (Since the terms explicit or declarative represent a human type of behaviour, it has
been suggested that the term relational memory would be more appropriate for animal
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research. Similarly, the term procedural memory is more suitable for animal research, instead
of implicit or non-declarative memory.) Studies with monkeys and rats have shown that the
HC and adjacent cortical structures are important for delayed recognition tasks and spatial
learning (relational memory), but not for learning stimulus-reward associations and motor
skills (procedural memory) (Eichenbaum et al., 1996). Because spatial learning and memory
can be investigated with behavioural tasks in man, monkey and rat, spatial behaviour provides
a link for investigating relational memory processes across species.
The final storage of lifelong memories takes place within the cortex, in the same regions that
are involved in the perception and analysis of the items to be remembered. Memories are
stored in component parts, geographically distributed across separate regions of the brain that
are needed to process the perception into a “memory engram” (Squire et al., 1993). The
explicit memory system needs interaction between the neocortex and limbic/diencephalic
brain systems, and is related to conscious recollections. The implicit memory system, which
provides for non-conscious responses to the world, needs the participation of those brain areas
responsible for the learning processes. Skill and habit memory requires participation of the
striatum, classical conditioning depends on the cerebellum, emotional conditioning depends
on the amygdala and priming takes place in the cortical areas responsible for perception
(Squire et al., 1993; Willingham, 1997).
In addition to the medial temporal lobe, another central brain area for memory is the
prefrontal cortex, which is considered to be important for working memory functions
(D'esposito and Grossman, 1996; Wagner, 1999). In the primate brain, the cortex of the
anterior pole of the frontal lobe excluding the motor and premotor cortex is commonly
designated the prefrontal cortex. Patients with damage to the prefrontal cortex have a deficit
in tasks assessing working memory, and modern studies with functional neuroimaging have
provided evidence of prefrontal cortex activation during working memory tasks (D'esposito
and Grossman, 1996). Similarly, monkeys with prefrontal lesions, specifically the principal
sulcus region of the dorsolateral prefrontal cortex, have disrupted performance in visuospatial
delayed response tasks, where the animal has to “keep in mind” the location of visual
stimulus over a delay (Rosenkilde et al., 1981). In addition, the prefrontal cortex of the
monkey brain shows increased metabolic activity during spatial delayed response tasks
(Friedman and Goldman Rakic, 1994). Furthermore, some of the prefrontal neurons have
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been shown to be active specifically during the delay period, which provides
electrophysiological evidence for the role of the prefrontal cortex in the maintenance of
working memory (Funahashi et al., 1989; Fuster, 1973). In rodents, the prefrontal cortex is
also important in the regulation of spatial working memory (Dunnett, 1990; Poucet, 1990;
Rogers et al., 1992; van Haaren et al., 1988). It is possible to compare the prefrontal cortex in
the rat, monkey and man using physiological and neural connectivity for defining the
prefrontal cortex. Across species, PFC can be defined as the “cortical areas for which the
reciprocal connections with the mediodorsal nucleus of the thalamus are stronger than are the
connections with other thalamic nuclei” (Uylings and van Eden, 1990). However, it should be
noted that the anatomical and functional characteristics of prefrontal cortex are much less
specific in rats than in primates, including humans. For example, in rats the rostral part of
frontal area 2 and the anterior cingulate area have primate premotor cortex characteristics, but
cannot be segregated from the prefrontal cortical areas (Uylings and van Eden, 1990). In
addition, different sub-areas of the prefrontal cortex have distinct roles in the regulation of
primate memory (Bachevalier and Mishkin, 1986; Dias et al., 1996; Wilson et al., 1993). For
example, the dorsolateral prefrontal cortex of primates is selectively involved with spatial
working memory, whereas the ventromedial part of the prefrontal cortex is necessary for
object recognition but not spatial working memory (Bachevalier and Mishkin, 1986). In
rodents, the area thought to be responsible for the regulation of spatial working memory is the
medial area in the upper edge and medial surface of the hemisphere. Prefrontal sub-areas can
also be found in the rat (Broersen et al., 1995; Dunnett, 1990; Eichenbaum et al., 1983; Kolb,
1984; Mogensen and Holm, 1994), although exact definitions of such sub-areas as functional
parts of rodent prefrontal cortex are still lacking.
In addition to working memory, the prefrontal cortex is important for the regulation of
attentional control of behaviour (Muir et al., 1996; Sarter et al., 2001). Attention is a complex
process and consists of several distinct mechanisms. Attention can be divided into sustained
attention (vigilance), divided attention and selective attention (Muir, 1996). Sustained
attention refers to a subject’s ability to detect rarely and unpredictably occurring signals over
prolonged periods of (Sarter et al., 2001). Divided attention refers to a subject’s ability to
attend to and process simultaneously more than one stimuli presented together, and selective
attention requires focusing of resources to a restricted number of sensory channels, typically
under some form of distraction (Muir, 1996). In rodents, attention can be further divided into
23
five categories: orienting, expectancy, stimulus differentiation, sustained attention, and
parallel processing (Bushnell, 1998). However, it is often difficult to distinguish
behaviourally between these processes, since overlapping attentional processes often
contribute to the behavioural outcome in attentional tasks (see (Bushnell, 1998) for a detailed
review).
Attentional processes in the mPFC are regulated by the ascending cholinergic fibers
originating from the NBM, specifically if demands on attentional processing are increased by
a distractor (Sarter et al., 2001). The NBM cholinergic cells are regulated by descending
glutamatergic projections from the prefrontal cortex, which provides a feedback mechanism
for attentional processing (Sarter et al., 2001). Behaviourally, it has been reported that
infusion of APV, an NMDA receptor antagonist, into the basal forebrain produces similar
effects on sustained attention as those resulting from cholinergic lesions. It is therefore likely
that stimulation of attentional processes in the cortex by ascending cholinergic fibers from the
NBM is regulated by NMDA receptors (Sarter et al., 2001).
2.2 Muscarinic receptors
2.2.1 Introduction: Brain cholinergic system
Acetylcholine. ACh is a neurotransmitter that is synthesized in cholinergic cells from choline
and acetyl-coenzyme A by the enzyme choline acetyltransferase (ChAT). The effects of ACh
are mediated by two groups of receptors: muscarinic and nicotinic receptors. Once released
from the pre-synaptic terminal, ACh is rapidly inactivated by hydrolysis into acetate and
choline by the enzyme AChE (Wilson et al., 1950). In the brain, cholinergic pathways arise
from small nuclei that contain cholinergic neurons intermingled with other, non-cholinergic
neurons (Mesulam, 1995). The highest density of cholinergic axons in the brain occurs in core
limbic structures, such as the HC and amygdala (Mesulam et al., 1992). Basically, cholinergic
cells form two systems, one in the basal forebrain and the other in the brainstem.
Basal forebrain. Cholinergic cells in the basal forebrain provide diffuse neural projections
that innervate the entire cerebral cortex. The density of cholinergic axons is highest in the
superficial layers of the cerebral cortex (Mesulam, 1995). The Ch1–Ch4 nomenclature
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designates the cholinergic cells within different nuclei (Mesulam, 1995; Mesulam et al.,
1983). Ch1 refers to cholinergic cells within the medial septal nucleus (MS), and Ch2 to those
within the vertical nucleus of the diagonal band. The main targets of Ch1 and Ch2 cholinergic
cells are the hippocampal formation, cingulate cortex, olfactory bulb and hypothalamus. Ch3
cells within the horizontal limb of the diagonal band nucleus (HDB) provide the major
cholinergic innervation for the olfactory bulb. Ch4 contains the cholinergic cells within the
nucleus basalis of Meynert (NBM) that provide cholinergic innervation for the rest of the
cerebral cortex and the amygdala (Mesulam, 1995; Mesulam et al., 1983).
Brainstem. The brainstem cholinergic system consists of four cholinergic cell groups, Ch5–
Ch8 (Mesulam, 1995; Mesulam et al., 1983). Ch5 designates cholinergic cells in the
pedunculopontine nucleus, and Ch6 cells in the laterodorsal tegmental nucleus and rostral
brainstem. The Ch5 and Ch6 cells project to the thalamus. Ch7 cells in the medial habenula
innervate the interpeduncular nucleus, and Ch8 cells in the parabigeminal nucleus project to
the superior colliculus. In addition to Ch1–Ch8 cells, there are intrinsic cholinergic
interneurons for example in the striatum.
2.2.2 Signal transduction and localization
Acetylcholine receptors can be divided into two major classes, nicotinic and muscarinic
receptors. Whereas nicotinic receptors are all ion channel receptors, muscarinic receptors are
linked to G- proteins. Nicotinic receptor is a pentamer composed of five homologous
membrane-spanning subunits (ABGD E=G) around a central ion channel (Paterson and
Nordberg, 2000). Several variants of each subunit have been characterized. Neuronal
nicotinic receptors generally comprise two a and three b subunits, the most common of which
is a beta2/alpha4 composition. In addition, a common neuronal nicotinic receptor consists of
five alpha7 subunits (Paterson and Nordberg, 2000). In general, the ion channel of the
nicotinic receptor is primarily permeable to Na+ and K+ ions, but the alpha7 receptor subtype
is also Ca2+ permeable (Girod et al., 2000). Opening of the channel results in an inward flux
of Na+ producing a local depolarisation of the membrane. In addition to postsynaptic sites,
there also exist pre-, peri- and extra synaptic nicotinic sites that may modulate neuronal
function through a variety of actions (Paterson and Nordberg, 2000).
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Fig. 2. Signal transduction of acetylcholine receptors.
Opening of the nicotinic receptor channel results in an inward flux of Na+, producing local
depolarisation of the membrane. In addition, the alpha7 receptor is also ca2+ permeable.
Activation of “odd” group receptors results in phospholipase Cβ activation that leads to
stimulation of phosphoinositide hydrolysis. Activation of “even” group G-protein leads to
inhibition of adenylate cyclase. Finally, activation of the M1 M2 and M3 receptors leads to
regulation of protein functions by phosphorylation, whereas activation of the M2 and M4
receptors results in a decreased cytosolic cAMP level.
This review focuses on muscarinic receptors, which will be described in greater detail in the
next chapter.
Subtypes. Muscarinic receptors belong to the superfamily of G-protein-coupled receptors
(Bonner et al., 1987). Typically, these receptors have seven transmembrane segments that
form a barrel-like structure having a central pore. ACh and other muscarinic ligands bind at a
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site inside this pore, which leads to activation of a G-protein (Hulme et al., 1990). Today five
muscarinic receptor subtypes, M1, M2, M3, M4 and M5 receptors, have been identified using
both pharmacological and molecular biological techniques (Caulfield and Birdsall, 1998). The
subtypes can be divided into two main groups that activate different G-proteins: an “odd-
numbered” group (M1, M3 and M5 receptors) and an “even-numbered” group (M2 and M4
receptors). At the cellular level, both groups of muscarinic receptors regulate the basal
activity of neurons. Activation of the “odd” group G-protein results in phospholipase Cβ
activation, which leads to the stimulation of phosphoinositide hydrolysis. Activation of the
“even” group G-protein leads to inhibition of adenylate cyclase (Caulfield and Birdsall,
1998). Finally, the activation of M1 M2 and M3 receptors leads to regulation of protein
functions by phosphorylation, whereas the activation of M2 and M4 receptors results in a
decrease in the cytosolic cAMP level (Caulfield and Birdsall, 1998).
Distribution. In general, the absolute density of muscarinic receptors is highest in the various
regions of the forebrain, but declines in more caudal regions of the brain (Ehlert et al., 1995).
The M1, M2 and M3 receptors represent the majority of muscarinic receptors in various brain
regions (table 2). The relative abundance of M1 receptors is greatest in the cerebral cortex (34
%), HC (47 %) and striatum (29 %) (Yasuda et al., 1993). The M2 receptor represents 75 % of
the total muscarinic receptors in the cerebellum, whereas in the cortex and HC the expression
is around 20 %. However, the absolute density of the M2 receptor is relatively uniform
throughout the brain (Li et al., 1991). The M2 receptor may act as a presynaptic autoreceptor,
a presynaptic heteroreceptor, or a postsynaptic receptor in the septo-hippocampal pathway
(Rouse et al., 1997). The M3 receptor has minor expression in the brain. The relative
expression of M3 receptor mRNA is greatest in the cerebral cortex and HC (11 %), but lower
in the more caudal regions of the brain (Yasuda et al., 1993). The M4 receptors have highest
expression in the striatum (46 %) and cortex (24 %). In the HC, the expression of M4
receptors is equal to that of M2 receptors (19 %) (Yasuda et al., 1993). The characterization of
the M5 receptor is still incomplete (Caulfield and Birdsall, 1998). Small amounts of the M5
receptor can be found in the substantia nigra, but the M5 subtype represents only 2% of the
total amount of muscarinic receptors in the brain (Caulfield and Birdsall, 1998; Yasuda et al.,
1993).
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Table 2. The relative expression of muscarinic receptor subtypes in major brain structures.
Brain area M1 M2 M3 M4 M5
Cortex 34 % 20 % 11 % 24 % < 2 %
Hippocampus 47 % 19 % 11 % 19 % < 2 %
Striatum 29 % 12 % 8 % 46 % < 2 %
Thalamus 16 % 43 % 6 % 20 % < 2 %
Cerebellum 2 % 75 % 5 % 3 % < 2 %
2.2.3 Cognitive functions mediated by muscarinic receptors
Central. Muscarinic receptors in the central nervous system (CNS) are involved in the
regulation of learning and memory functions. Originally, Drachman and Leavitt (Drachman
and Leavitt, 1974) found that the muscarinic antagonist, scopolamine, produced amnesia in
young volunteers similar to that observed in aged non-demented people (Bartus et al., 1982).
In rodents, scopolamine is known to disrupt performance in spatial learning and memory
tasks (Andrews et al., 1994; Buresova et al., 1986; Riekkinen et al., 1990; Sirviö et al., 1992).
However, the cognitive effects mediated by muscarinic receptors are not specific to learning
and memory, since muscarinic receptors also mediate processes that are needed in the
regulation of attention and arousal (Broks et al., 1988; Callahan et al., 1993; Parrott, 1986;
Phillips et al., 2000; Ruotsalainen et al., 2000). It is possible, that disruption of attentional and
other non-cognitive processes in the CNS is the actual cause of the learning and memory
deficits caused by muscarinic antagonists (Blokland, 1996; Ebert and Kirch, 1998).
Classically, muscarinic receptors have been divided into M1 and M2 receptors, with high and
low affinities to muscarinic receptor antagonist pirenzepine, respectively. Muscarinic receptor
subtypes mediate different aspects of behaviour, and there are reports indicating that post-
synaptic M1 receptors mediate the performance-disrupting effects of scopolamine. For
example, in the water maze and radial arm maze tasks, pirenzepine, a selective M1 antagonist,
causes performance disturbance similar to that with scopolamine or atropine (Hagan et al.,
1987; Hunter and Roberts, 1987; Sala et al., 1991). In addition, pirenzepine has been reported
to cause more specific effects on spatial short-term memory performance than scopolamine in
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the delayed non-matching to position task (DNMTP) (Andrews et al., 1994). In this study, the
result of pirenzepine administration was a delay-dependent disruption of performance,
whereas scopolamine induced a non-specific and delay-independent disruption of all task
parameters, including motivation and motor performance (Andrews et al., 1994). In the same
study, an M2 receptor antagonist (AFDX 116) had no effect on DNMTP performance,
suggesting that the M2 receptors do not mediate the disrupting effect of muscarinic
antagonists on spatial short-term memory. In theory, it is possible that blockade of
presynaptic M2 receptors enhances the function of ACh system by increasing the release of
ACh, which may lead to beneficial effects on cognitive behaviour (Quirion, 1993; Quirion et
al., 1995).
Genetic receptor inactivation. A novel approach to defining the role of muscarinic receptors
in the CNS is the use of receptor knockout mice that lack a specific subtype of an mACh
receptor. Knockout studies support the role of M1 receptors as the primary mediator of
postsynaptic muscarinic receptor signalling in the cortex and hippocampus (Porter et al.,
2002). It has also been reported that M1 receptor knockout mice show impaired spatial water
maze learning (Hamilton et al., 2001), but this may not be a memory-specific effect due to
pronounced non-specific hyperactivity caused by the gene deletion (Miyakawa et al., 2001).
Thus far, knockout studies have revealed that the M3 subtype plays a key role in salivary
secretion, pupillary constriction, and bladder detrusor contractions (Matsui et al., 2000),
whereas the M3 receptors have no significant role in ACh-induced G-protein signalling in the
the cortex and hippocampus (Porter et al., 2002). Knockout studies also support the role of M2
receptors as the main presynaptic autoreceptor in the cortex and hippocampus, whereas in the
striatum the autoinhibition is predominantly mediated by the M4 receptors (Zhang et al.,
2002). Central M2 receptors are critically involved in mediating tremor, hypothermia and
analgesia, whereas the M4 receptor knockout mice have increased basal motor activity (Felder
et al., 2001; Gomeza et al., 2001). M4 receptors are also involved in the regulation of prepulse
inhibition of the startle reflex, a measure of attention (Felder et al., 2001). The M5 muscarinic
receptor knockout mice have been reported to be intact in various behavioural tests, but ACh
is not able to dilate cerebral arteries and arterioles in these knockout mice, suggesting that the
receptor is physiologically relevant in the regulation of cerebral blood flow (Yamada et al.,
2001).
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What is problematic about the use of gene-manipulated mice is that compensatory
mechanisms during embryonal development may alter the normal physiological balance, thus
making it difficult to determine the actual role of receptor subtypes in the regulation of on-
line behaviour. One way to limit developmental abnormalities is to use inducible gene
manipulation affecting only one specific brain area at a specific time. Thus far, such studies
have provided interesting data on NMDA receptors, though there is still a clear lack of studies
focusing on muscarinic ACh receptors.
Peripheral. Muscarinic receptors also mediate peripheral responses, especially responses of
the autonomic nervous system. Muscarinic antagonists induce peripheral side effects that may
contribute to the behavioural effects of these drugs. For example, scopolamine causes blurred
vision by reducing accommodation, decreases resting heart rate, causes urinary retention and
reduces salivation which may decrease appetite (Stromberg et al., 1991) (Parrott, 1989)
(Parrott, 1987). Some of the peripheral effects can be used for treatment purposes. For
example, scopolamine blocks the auriculoemetic reflex and reduces intestinal secretion
(Honkavaara and Pyykko, 1999; Muir and von Gunten, 2000), which can be used for
protection of motion sickness and perioperational nausea (Parrott, 1989; Stromberg et al.,
1991). Still, if one is interested in investigating brain memory processing, even these
peripheral effects may not be desired and should be minimised.
AChE inhibitors. Inhibition of AChE leads to an increase in ACh concentration within the
synaptic cleft, thus prolonging and increasing the binding of ACh into the receptors. In
rodents, scopolamine-induced spatial learning and memory deficit in the water maze and
DNMTP tasks can be alleviated by AChE inhibitors, such as tetrahydroaminoacridine (THA),
metrifonate and rivastigmine (Bejar et al., 1999; Murray et al., 1991; Riekkinen et al., 1991;
Riekkinen et al., 1996). In addition, THA is able to improve water maze performance in aged
and MS lesioned rats (Riekkinen et al., 1991; Riekkinen et al., 1996). According to the
cholinergic hypothesis of AD, stimulation of the brain cholinergic system should alleviate AD
symptoms (Bartus et al., 1982). In AD patients, AChE inhibitors, such as THA, donepezil and
rivastigmine, provide relief of AD symptoms, but the cognitive effects are modest at best
(Emilien et al., 2000; Francis et al., 1999). Moreover, the AChE inhibitors are more efficient
in relieving hallucinations and defects in attentional and arousal processes, than memory
impairment per se (Francis et al., 1999).
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Cholinergic lesion. Recently, the development of a selective cholinergic neurotoxin, IgG-
saporin, has provided new information on the role of the brain cholinergic system in cognition
(McGaughy et al., 2000). IgG-saporin is a neurotoxin that binds to low-affinity nerve growth
factor receptor p75, inducing apoptotic cell death in cholinergic cells. Only the projections
from Ch5 and Ch6 to the thalamus, and the projection from Ch4 to the amygdala, are not
sensitive to IgG-saporin (McGaughy et al., 2000). Studies using i.c.v. administration of IgG-
saporin have shown that damage of the basal forebrain cholinergic cells disrupts acquisition
of water maze tasks only if there is additional damage to cerebellar Purkinje cells (McGaughy
et al., 2000; Waite et al., 1999). More selective lesions of MS and/or NBM cells have no
effect on the acquisition of water maze tasks, suggesting that neither the septo-hippocampal
nor cortical cholinergic innervation is needed for spatial learning (Baxter et al., 1996).
However, selective lesioning of cholinergic cells in MS is able to produce delay-dependent
impairment in the delayed matching to position task (DMTP), suggesting that the septo-
hippocampal pathway is important for the regulation of spatial short-term memory (Torres et
al., 1994). Nevertheless, even selective cholinergic lesions of basal forebrain induce non-
specific behavioural disturbance, such as hyperactivity (Torres et al., 1994). Correspondingly,
disturbance of attention or arousal is likely to contribute to the disruption of cognitive
functions by cholinergic lesioning, as reflected by disruption of performance in sustained
attention and serial conditioning tasks (McGaughy et al., 2000).
2.2.4 Muscarinic receptors in aging and AD
Aged rats. Spatial learning deficit in aged rats has been used as a model for the cognitive
decline related to aging and AD (Barnes, 1994). The anatomical and physiological changes
occurring in the aged rodent brain resemble those occurring in AD. For example, the decrease
in the ACh synthesizing enzyme ChAT during aging may reflect degeneration of cholinergic
cells in the basal forebrain, although the evidence supporting a ChAT decrease in the rodent
brain is somewhat contradictory for both the cortex and HC (table 3). In addition, AChE
activity is decreased in both AD (Namba et al., 2002) and rodent aging (table 3). Aged rats,
like young rats with hippocampal damage, show greater impairment in water maze learning
than do young controls (Gage et al., 1989; Gallagher et al., 1994). Those aged rats that are
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most severely impaired in spatial tasks also have the greatest amount of degeneration in
cholinergic cells in the basal forebrain, which further supports the view that the degeneration
of the septohippocampal cholinergic system is linked to age-related learning impairment
(Gallagher et al., 1994; Rapp and Amaral, 1992). Furthermore, the function of muscarinic
receptors may be disrupted over the course of aging, since both memory-impaired and
memory-intact aged rats are more sensitive to the disrupting effects of scopolamine than
young rats (Gallagher et al., 1994). The spatial learning deficit of aged rats can be used for
investigating the efficacy of drugs in improving memory function, and the results from such
studies may help in finding new treatments for the cognitive decline seen in AD.
At the receptor level, there seems to be a decline in the total density of muscarinic receptors
in the cortex and HC of aged rats, when compared to young controls (table 3). In the cortex,
both muscarinic M1 and M2 receptor subtypes decrease during aging; whereas, in the HC,
sparing of both M1 an M2 subtypes has been reported (table 3). In different rat strains the
cholinergic system may be differentially changed during aging (Michalek et al., 1990). In
Wistar rats, a decrease in both cortical and hippocampal muscarinic receptors and AChE
activity has been reported during aging in Wistar rats that were used for our experiments
(table 3).
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Table 3. Changes in AChE and ChAT activity and muscarinic receptor density during rodent
aging.
ChAT act AChE
activity
All MR:s M1 M2
Cortex ↓ 3,6,7 O 7,7,11 ↓ 7,7,7,11, ↓ 4,5,7,12 O 7,7 ↓ 1,5,8    O 6 ↓ 1,6,8
HC ↓ 3  O 5,7,7,7,11 ↓ 7,7,7,11, ↓ 4,7,7,9  O 5,14 ↓ 1,2,13  O 5,6,8,10,14 ↓ 1,6  O 2,8,14
Striatum ↓ 3,7,7,7  O 5 ↓ 7,7,7,11 ↓ 4,7,7    O 5 ↓ 1,8   O 5,6 ↓ 1,6,8
1) Fisher 344 (Narang, 1995)
2) Wistar (Amenta et al., 1995)
3) Fisher 344 (Ogawa et al., 1994)
4) Rats (Blake et al., 1991)
5) Fisher 344 (Schwarz et al., 1990)
6) Rats (Araujo et al., 1990)
7) Fisher 344, Sprague Dawley and Wistar (Michalek et al., 1990)
8) Rats (Biegon et al., 1989)
9) Wistar (Kadar et al., 1994)
10) Wistar (Sirviö et al., 1988)
11) Wistar (Sirvio et al., 1989)
12) Wistar (Gilad et al., 1987)
13) Fisher 344 (Tayebati et al., 2002)
14) Long-Evans (Chouinard et al., 1995)
Table 4. Changes in AChE and ChAT activity and muscarinic receptor density in Alzheimer's
disease.
ChAT
activity
AChE
activity
All MR:s M1 M2 M3 M4
Cortex ↓ 1,2,7 ↓ 7,12 ↓ 2,4 O9 ↑ 7,8 ↓ 3*,4 O 1,2,3 ↑ 5 ↓ 1,2,3,3* O 6 ↑ 5 O 4 ↑ 3,3*O 4
HC ↓ 1,2,7 ↓ 7,12 ↓ 2,4,10 ↓ 4,11  O 2   ↓ 1,2,4,6 ↓ 4 O 4
Striatum ↓ 7 ↓ 10  ↑ 7 ↑ 1 O 1   ↑ 4  O 4 O 4
1) (Aubert et al., 1992)
2) (Quirion et al., 1989)
3) (Flynn et al., 1995)
4) (Rodriguez-Puertas et al., 1997)
5) (Nordberg et al., 1992)
6) (Rinne et al., 1989)
7) (Danielsson et al., 1988)
8) (Nordberg and Winblad, 1986)
9) (Perry et al., 1990)
10) (Rinne et al., 1985)
11) (Shiozaki et al., 2001)
12) (Namba et al., 2002)
* = immunoreactivity vs radioligand binding
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Aging and Alzheimer’s disease. AD is the most common cause of memory loss and dementia
in elderly people. The cholinergic hypothesis by Raymond Bartus posits that degeneration of
the brain cholinergic system is linked to the cognitive symptoms of AD (Bartus et al., 1982).
In the course of the disease, cholinergic cells in the NBM and other parts of the basal
forebrain die, resulting in decreased cholinergic innervation particularly in the temporal lobe
(Geula and Mesulam, 1996). The degeneration of the brain cholinergic system is strongly
correlated with the degree of cognitive impairment in AD patients, and occurs early in the
course of the disease (Bartus, 2000; Francis et al., 1999). In AD, cholinergic cell death is
reflected by a reduction in presynaptic markers of the cholinergic system, i.e. by a reduction
in cortical ChAT activity and ACh synthesis (Francis et al., 1999).
At the receptor level, there is little or no difference between normal aged people and AD
patients in the overall expression of cortical muscarinic receptors (Perry et al., 1990; Schroder
et al., 1991) (table 4). The M1 receptor subtype in the cortex has generally been reported to be
preserved in AD (table 4). However, coupling of M1 receptors to their G-proteins may be
disrupted in AD brains (Flynn et al., 1995; Warpman et al., 1993). The M1 receptors in the
HC are suggested to be either preserved or decreased (table 4). Cortical M2 receptors appear
to be decreased in AD, though preservation and even an increase have been reported (table 4).
Several different studies agree that a decrease in hippocampal M2 receptors occurs in AD,
which is thought to reflect pre-synaptic degeneration of cholinergic fibres in the HC (table 4).
The M3 receptors have been reported to be preserved in the cortex, but decreased in the HC.
The M4 receptors are either preserved or increased in the cortex and preserved in the HC
(table4). The expression of the M5 receptor subtype in AD has been reported to remain
unchanged (Flynn et al., 1995).
2.3 N-methyl-D-aspartate (NMDA) receptors
2.3.1 Introduction: glutamatergic receptors
Glutamate is a nonessential amino acid that serves as the predominant excitatory
neurotransmitter in the mammalian brain. It is a neurotransmitter having numerous clinically
important pathways, as well as a crucial role in cortical and hippocampal cognitive function,
motor function, and sensory function (Greenamyre and Porter, 1994). Glutamate activates
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several classes of receptors, each of which has a distinct pharmacology, biochemistry and
physiology. Glutamate receptors are classified into two major categories termed ionotropic
and metabotropic receptors. Ionotropic receptors are linked to ion channels that are permeable
to Na+ or Ca2+ cations. They have been classified into three major subtypes that have different
relative permeability to Na+ or Ca2+: NMDA, α-amino-3-hydroxy-5-methyl-4-isoxazole
proprionic acid (AMPA) and kainate receptors (Dunah et al., 1999). The subtypes are named
according to the agonists that are able to elicit a specific physiological response. The structure
and function of the NMDA receptors are described in detail in the next chapter. The AMPA
receptors mediate the majority of the fast excitatory neurotransmission in the CNS.
Generally, activation of the AMPA receptor results in a Na+ influx, though some subtypes are
also permeable to Ca2+ (Greenamyre and Porter, 1994). Kainate receptors are also mainly
permeable to Na+, although the physiological and pharmacological properties vary depending
upon the subunit composition of the individual receptor (Greenamyre and Porter, 1994). The
other category, metabotropic glutamate receptors, couples to G-proteins and cytoplasmic
enzymes. Depending on the receptor subtype, these receptors mediate such processes as
inositol phosphate metabolism, the release of arachidonic acid or changes in cyclic adenosine
monophosphate levels (Greenamyre and Porter, 1994).
2.3.2 NMDA receptor structure and signal transduction
The NMDA receptor is the best defined of all glutamate receptors, among which it has unique
characteristics. The receptor itself (Fig. 3.) has binding sites for two “co-agonists”, glutamate
and glycine, both of which are needed for full receptor activation. The NMDA receptor is
gated both by ligands and by voltage, thus requiring depolarization of the postsynaptic
membrane before the binding of ligands results in a cation influx (Meldrum, 2000; Mori and
Mishina, 1995). This voltage dependence is due to a Mg2+ block within the ion channel,
which is removed by membrane depolarization (Mori and Mishina, 1995). Usually, the
depolarization is caused by activation of the AMPA receptors that have faster kinetics than
the NMDA receptors. Electrophysiologically, activation of the AMPA receptor can be seen as
the fast initial component of excitatory postsynaptic potential (EPSP), whereas the EPSP
mediated by the NMDA receptor displays a slower and prolonged time course (Mori and
Mishina, 1995). NMDA receptor activation is also modulated by polyamines, such as
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spermine and spermidine. Polyamines are not needed for receptor activation, but they increase
the ability of glutamate and glycine to open the receptor ion channel (Greenamyre and Porter,
1994). Unlike the other ionotropic receptors, the NMDA receptors are highly permeable to
Ca2+. The result of the Ca2+ influx is an activation of several Ca2+ dependent enzymes, such as
protein kinase C, phospholipase C, Ca2+ protein kinase II, nitric oxide synthase and various
proteases and endonucleases (Greenamyre and Porter, 1994). Some of the Ca2+ dependent
enzymes phosphorylate either AMPA or NMDA receptors, resulting in increased activity of
the receptors. The activation of Ca2+ dependent enzymes may also lead to transcription of
several genes, which in turn leads to prolonged changes in the receptor structure and activity,
i.e. synaptic plasticity (Michaelis, 1997).
The NMDA receptors consist of several subunits. In the rat, these subunits can be divided into
two families, NMDAR1 (NR1) and NMDAR2 (NR2). The NR2 family has four members,
NR2A - D (Mori and Mishina, 1995). Both families also have numerous splice variants.
Functional receptors express the subunit NR1 combined with NR1 or with one of the
members of the NR2 family. In the mouse, NR1 and NR2A-D are named GluRzeta and
GluRepsilon1-4, respectively. The NMDA receptor subtypes have different distributions in
the brain. For example, NR1 is the predominant subunit type in the HC and cerebral cortex,
while NR2A is also highly expressed in the septum, the caudate putamen, the olfactory bulb
and the thalamus. In addition, the NMDA receptor subtypes have different gating properties
and sensitivities to Mg2+ and Ca2+ (Mori and Mishina, 1995)
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Fig. 3.. Schematic representation of the NMDA receptor and the binding sites of major
agonists, antagonists and allosteric modulators.
2.3.3 Behavioural functions mediated by NMDA receptors
Antagonists. The psychopharmacological profile of the NMDA receptor antagonists is
complex. NMDA antagonists have anxiolytic effects and potent anticonvulsant properties, are
muscle relaxants and may even act as behavioural stimulants (Cotman and Iversen, 1987). In
humans, the cognitive effects of NMDA antagonists are not limited to learning and memory
functions. For example, NMDA antagonists are able to induce different types of memory
impairments, but are also known for their capability to induce hallucinations and other
schizophrenia-like symptoms including disturbed attention (Hetem et al., 2000; Malhotra et
al., 1996; Newcomer et al., 1999; Oranje et al., 2000). In rodents, NMDA antagonists disrupt
performance in various memory tasks, including tasks that assess spatial learning and spatial
short-term memory (Cole et al., 1993; Davis et al., 1992; DeNoble et al., 1990; Ward et al.,
1990), and have also been shown to have non-cognitive effects (Cole et al., 1993; Doyle et al.,
1998; Parada-Turska and Turski, 1990; Pontecorvo et al., 1991). Therefore, it is likely that the
sensorimotor disturbance caused by NMDA antagonists may contribute to  spatial learning
and memory deficits (Cain, 1998; Doyle et al., 1998; Saucier et al., 1996). The effect profiles
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of different NMDA antagonists vary, with non-competitive antagonists appearing to have
more robust behavioural effects than competitive antagonists (Cole et al., 1993).
D-cycloserine. Use of NMDA agonists in cognitive research is problematic, since NMDA
receptor activation may lead to calcium-mediated cell death. NMDA itself can be used to
make lesions in the brain (Myhrer, 1993), and one theory even suspects NMDA receptor
mediated exicotoxicity to be involved in cell death occurring in AD (Maragos et al., 1987).
However, positive modulation of NMDA receptors, instead of direct agonism, may provide
beneficial effects on cognition without cell degeneration. D-cycloserine (DCS) is a positive
modulator of the strychnine insensitive glycine site in the NMDA receptor, i.e. binding of
DCS to its binding site enhances the natural function of the NMDA receptor. It is found as an
endogenous ligand in both the rodent and human brain. In humans, DCS alleviates
scopolamine induced cognitive decrements (Jones et al., 1991) and has beneficial effects for
cognition in AD patients (Schwartz et al., 1996; Tsai et al., 1999). In rodents, DCS is able to
alleviate the age-related (Popik and Rygielska, 1999) and scopolamine-induced spatial
learning deficit (Pitkänen et al., 1995; Puumala et al., 1998).
 Genetic receptor inactivation. Studies with genetically engineered mice have revealed that
the NMDA receptors have a vital role in normal development. Homozygous knockout mice
totally lacking the NR1 subunit, and thus functional NMDA receptors, have
neurodevelopmental abnormalities and die soon after birth from respiratory failure (Forrest et
al., 1994; Li et al., 1994). Knockout mice having reduced levels of NMDA receptors exhibit
behavioural disturbances varying from impaired synaptic plasticity, learning and memory
(Sakimura et al., 1995) to hyperlocomotion, increased stereotypy and abnormalities in social
and sexual interactions (Mohn et al., 1999).
Mice that lack the NR1 subtype specifically in the CA1 field of the hippocampus have
provided a new approach for investigating the brain NMDA receptors. These knockout mice
grow into adulthood normally but have impaired spatial memory and long-term potentiation,
supporting the idea that hippocampal synaptic plasticity mediated by the NMDA receptors is
needed in the regulation of spatial memory (Tsien et al., 1996). In addition, studies in CA1
specific NR1 knockout mice suggest that hippocampal NMDA receptors are also needed for
the encoding and flexible expression of stimulus relations in non-spatial memory (Huerta et
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al., 2000; Rondi-Reig et al., 2001).
Functional glycine binding sites are essential for normal NMDA receptor function, since
homozygous animals with severely dysfunctional glycine sites do not survive (Kew et al.,
2000). However, a milder reduction in the agonist-binding capacity of functional glycine sites
in mice with targeted point-mutations results in an impairment of spatial learning and
hippocampal LTP. Reduced levels of glycine sites are also known to cause alterations in
anxiety-related behaviour (Kew et al., 2000).
2.3.4 NMDA receptors in aging and AD
Table 5. Changes in NMDA receptor density during aging in rats.
Brain area NMDAR:s
Cortex ↓ 1,2,5,6,106*,7*,9* O 3,7
HC ↓ 2,5,6,10 6*,7*, 9* O 3,4, 7,8*
Striatum ↓ 1,2,4,5,10
1) Fisher 344 (Mitchell and Anderson, 1998)
2) Female wistar (Wardas et al., 1997)
3) Fisher 344 (Shimada et al., 1997)
4) Long evans (Nicolle et al., 1996)
5) Fisher 344 (Castornia et al., 1994)
6) Fisher 344 (Tamaru et al., 1991) *
7) Fisher 344 (Kito et al., 1990) *
8) Fisher 344 (Bonhaus et al., 1990) *
9) Fisher 344 (Miyoshi et al., 1990) *
10) Wistar (Serra et al., 1994)
* = glycine site studied.
Aged rats. The number of NMDA receptors in the cortex and HC declines during aging,
although preservation in both areas has also been reported (table 5). However, the number of
NMDA receptors containing the strychnine insensitive glycine binding site has consistently
been reported to decrease during aging (Kito et al., 1990; Miyoshi et al., 1990; Tamaru et al.,
1991) (table 5). A similar trend is also evident in the striatum, where the number of NMDA
receptors declines during aging (table 5)
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Alzheimer’s disease. The number of NMDA receptors is reduced in the cortex and HC in AD,
although sparing has also been reported (table 6). NMDA receptors in different cortical areas
may be differentially affected in AD (Scheuer et al., 1996). By contrast, the NMDA receptors
seem to be spared in the striatum (table 6).
Table 6. Changes in NMDA receptor density in Alzheimer’s disese
Brain area NMDAR:s
Cortex ↓ 2,4,7*,9*,10,12O3,5,8
HC ↓ 2,6,12 O1,3,5,11
Striatum O3,4
1) (Geddes and Cotman, 1986)
2) (Young, 1987)
3) (Cowburn et al., 1988)
4) (Simpson et al., 1988)
5) (Mouradian et al., 1988)
6) (Penney et al., 1990)
7) (Del Bel and Slater, 1991) *
8) (Porter et al., 1992)
9) (Carlson et al., 1993) *
10) (Scheuer et al., 1996)
11) (Thorns et al., 1997)
12) (Wang et al., 2000)
* = glycine site studied.
2.4 Interaction between muscarinic and NMDA receptors in learning and memory
functions
Receptors. Muscarinic and NMDA receptors may interact at the synaptic level to modulate
neuronal activity. For example, cholinergic synaptosomes from the cerebral cortex are able to
co-release glutamate, indicating the coexistence of ACh and glutamate in the same cells
(Docherty et al., 1987). Moreover, within the cortex, ACh can increase the release of glycine,
a potent positive modulator of NMDA receptors (Russo et al., 1993), and both glutamate and
NMDA increase the release of ACh from rat cortical and striatal slices (Ulus et al., 1992).
Furthermore, electrophysiological data suggests that the induction of long-term potentiation
(LTP) is stimulated by both muscarinic and NMDA receptors (Hirotsu et al., 1989) which can
thus modulate the neuronal processing required for memory functions in the cortex and HC.
Behaviour. Preliminary evidence suggesting that NMDA and muscarinic receptors interact in
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the regulation of memory processes comes from primate research, indicating that MK-801 (a
non-competitive NMDA antagonist) and scopolamine, given in subthreshold doses, jointly
disrupt memory performance in visual recognition tasks. In rodents, both NMDA antagonists
and scopolamine induce performance deficits in spatial learning tasks, but the effects may not
be specific to memory (Cain, 1998; Saucier et al., 1996). Findings showing that combined
scopolamine and MK-801 administration at subthreshold doses produces short-term amnesia
in the elevated plus maze task and impairs inhibitory avoidance learning suggest that there is
an interaction between muscarinic and NMDA receptors in the regulation of basic memory
processes. Interaction in the regulation of spatial learning and memory is supported by studies
showing that DCS reverses the acquisition deficit induced by scopolamine in the water maze
(Pitkänen et al., 1995; Puumala et al., 1998; Sirviö et al., 1992), T-maze (Fishkin et al., 1993)
and passive avoidance tasks (Zajaczkowski and Danysz, 1997). In the radial arm maze task,
NMDA antagonists have been shown to potentiate the scopolamine induced amnesic effect
(Li et al., 1997). Furthermore, our laboratory has found that subthreshold doses of
scopolamine and DCS in the dorsal HC induce an acquisition deficit in the water maze task,
suggesting that muscarinic and NMDA receptors jointly modulate spatial navigation at the
hippocampal level (Riekkinen and Riekkinen, 1997). Interaction at the hippocampal level is
further supported by the finding that DCS reduces the scopolamine-induced deficit of
working memory, as assessed in a three-panel runway task (Ohno and Watanabe, 1996).
Interestingly, physostigmine does not reverse working memory deficit induced by
microinjections into the HC of the competitive NMDA receptor antagonist ((+/-)-3-(2-
carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), suggesting that disrupted NMDA
receptor mediated mechanisms regulating working memory in this task cannot be restored
with muscarinic receptor stimulation in the HC (Ohno et al., 1996). Pharmacological evidence
also favors the importance of colinergic and NMDA receptor dysfunction in the cognitive
decline of aged rats, as indicated by the finding that THA and DCS dose dependently
alleviated failures in water maze spatial navigation induced by aging in rats (Baxter et al.,
1996; Riekkinen et al., 1996).
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3. AIMS OF THE STUDY
The purpose of this study was to investigate the role of cholinergic system and muscarinic
ACh receptors, as well as their possible interactions with glutamatergic NMDA receptor
mediated mechanisms in the modulation of working memory and the age-related spatial
navigation deficit of rats. The specific aims were as follows.
1. To study whether blockade of central NMDA or muscarinic receptors, especially the M1
and M2 subtypes, affects working memory by investigating the effects of the NMDA
antagonist CPP or the muscarinic receptor antagonists scopolamine, pirenzepine and
methoctramine on the performance of rats in the delayed non-matching to position
(DNMTP) task (I and II).
2. To examine whether central muscarinic and NMDA receptor mediated mechanisms
interact in the modulation of working memory by comparing the effects of combined and
separate blockade of these receptors on DNMTP task performance (II).
3. To investigate whether blockade of muscarinic or NMDA receptors in the dorsomedial
prefrontal or dorsolateral frontal cortex affects working memory by determining the
effects of intracerebral injections of scopolamine and CPP on DNMTP task performance
(III).
4. To study the interaction between cholinergic (THA) and NMDA receptor (DCS)
stimulation in alleviating the spatial navigation deficit of aged rats by using either
separate or combined administration of these drugs and several variants of the water maze
task (IV and V).
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4. MATERIALS AND METHODS
4.1 ANIMALS
Male Han:Wistar rats were used in this study. The animals were singly housed in stainless
steel shoe-box cages (44 x 27 x 15 cm; l x w x h) in a controlled environment (National
Laboratory Animal Centre, Kuopio, Finland; temperature 20°C, humidity 50-60%, lights on
from 07.00 to 19.00 hours) with water and food freely available during water maze testing (IV
and V). During training and testing of the DNMTP task, the rats were deprived of food 12-14
h before daily training or testing (I - III). After daily behavioural training or testing in the
DNMTP task, the rats received 10-12 g of food pellets (Special diet service, England), thus
enabling the animals to be maintained at 80 – 85 % of their free-feeding weight. Water was
freely available except in the test apparatus. The studies were conducted according to EC
guidelines and were approved by the State Provincial Office of Kuopio.
4.2 IMPLANTATION OF INFUSION CANNULAS
The rats were anaesthetised and placed in a stereotaxic frame (I - III). The guide cannulae
were implanted unilaterally in the lateral ventricle (I and II) or bilaterally in the dmPFC (Fig.
4.) or dlFC (III). The implantation of infusion cannulae is described in more detail in
publications I - III.
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Fig. 4. The location of cannulae tips in the dmPFC (marked by asterisks). The numbers
represent millimetres anterior to the bregma (adapted from Paxinos and Watson, 1986).
Abbreviations (according to (Krettek and Price, 1977)): Fr2 = frontal area 2; ACd = dorsal
anterior cingulate area; PL = prelimbic area; MO/VO = medial / ventral orbital area.
4.3 PHARMACOLOGICAL AGENTS
The following pharmacological agents were used in the experiments: a non-selective
muscarinic antagonist, scopolamine (Sigma Chemical Company, St. Louis, MO, USA); a
selective muscarinic M1 receptor antagonist, pirenzepine (Research Biochemicals
International (RBI), Natick, MA, USA); a selective muscarinic M2 receptor antagonist,
methoctramine (RBI); a cholinesterase inhibitor, tetrahydroaminoacridine (THA) (RBI); a
partial agonist of the glycine-B -site of the NMDA receptor, D-cycloserine (DCS) (RBI); and
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a selective NMDA receptor antagonist, CPP ((+/-)-3-(2-carboxypiperazin-4-yl)propyl-1-
phosphonic acid (RBI)).
Table 7. Antagonist affinities of muscarinic receptor subtypes in numeric and scale form.
(adapted from (Girdlestone, 1998).
M1 M2 M3 M4 M5
Scopolamine (Kd) 80-150 200-400 150-250 50-100 500-700
Scopolamine (pKd) 9.8-10.1 9.4-9.7 9.6-10.1 10-10.3 9.2-9.3
Pirenzepine(pKd or pKB) 7.8-8.5 6.3-6.7 6.7-7.1 7.1-8.1 6.2-7.1
Methoctramine (pKd or pKB) 7.1-7.8 7.8-8.3 6.3-6.9 7.4-8.1 6.9-7.2
Publication I addressed the effects of i.c.v. infusions of scopolamine (3 and 10 µg),
pirenzepine (10 and 30 µg) and methoctramine (2 - 20 µg) on DNMTP task performance.
Publication II addressed the effects of i.c.v. infusions of scopolamine and pirenzepine given
in combination with CPP at sub-threshold doses on DNMTP task performance.
Publication III addressed the effects of i.c. infusions of scopolamine (10 µg) and CPP (0.01 –
0.1 µg) into the dmPFC and scopolamine (10 µg), and CPP (0.1 and 0.3 µg) into the dlFC on
DNMTP task performance.
Publication IV addressed the effects of THA (3 mg / kg) and DCS (10 mg / kg), either
separately or in combination, on the spatial navigation of aged rats in the water maze task.
Publication V addressed the effects of THA (3 mg / kg) and DCS (10 mg / kg), either
separately or in combination, on the spatial navigation of the aged rats after pre-training.
5 6 7 8 9 10 11
M 5 M 2 M 4M 3M 1
M 5M 2 M 4M 3 M 1
M 5 M 2M 4M 3 M 1
pK d
scop:
pirenz:
m etho:
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4.4 BEHAVIOUR
4.4.1 Delayed non-matching to position task (DNMTP) (publications I - III)
Apparatus: DNMTP testing was conducted in four operant chambers, each equipped with two
retractable levers and a food pellet dispenser (Campden Instruments, London, UK). The
operant chambers were under the online control of microprocessors (Paul Fray Ltd.,
Cambridge, UK) programmed using Spider (Paul Fray Ltd., Cambridge, UK) (Sirviö et al.,
1991). The food pellet dispenser was located between the levers and delivered 45 mg of
dustless precision pellets (Campden Instruments, UK).
Training: Prior to training for the DNMTP task, 35 rats at the age of three months were first
deprived of food overnight, and 5 rats were kept on a free feeding regimen as age-matched
weight controls. The weights were kept at approximately 85 % of their free feeding weight by
giving them a daily 10 – 12 g dose of food pellets (Special Diet Service, UK). During the first
week, the weights of the rats were controlled daily; during the second two weeks, twice a
week; and during the rest of the time, once a week.
Before the actual training started, the rats were first habituated to the chamber for 10 min. The
perspex door of the food pellet dispenser was open and the magazine was filled with reward
pellets, thus assuring that the rats would learn to associate the magazine with the reward
pellets. The actual training schedule was adapted from Sirviö et al. (1991).
In the first phase of training, the rats were trained to collect food pellets and to associate the
click of the dispenser plus illumination of the panel light with pellet delivery. A pellet was
delivered every time a rat made a nose poke into an illuminated pellet magazine. If a rat did
not respond within 45 s, the magazine light was turned off for 5 s. The rats were trained 20
minutes/day until they had learned to obtain at least two pellets/minute. All the rats learned to
collect pellets within 3 days.
In the second phase, the rats learned to associate the lever press with the delivery of a food
pellet. Both levers were inserted and, every time a rat pressed a lever, a food pellet was
delivered into the magazine, which was illuminated. If a rat did not react within 45 s, the
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levers were retracted for 5 s. The rats needed one or two training periods in phase two to learn
the task (more than one response/ minute).
In phase three, rats learned to press a lever (either right or left) when it was inserted into the
chamber in order to get a food pellet. The right or left lever was inserted randomly, and if the
rat pressed the lever, a food pellet was delivered and the magazine was illuminated. Then the
lever was retracted, and after a 5-s period, one of the levers was inserted once again. If a rat
did not press the lever within 45 s, the lever was retracted and the house light was turned off
for 5 s. All the rats tested in phase three acquired the task in one session (more than one
response/minute).
In phase four, the rats were trained for the non-matching to position task (0-delay). A right or
left lever, which was selected randomly, was inserted into an operant chamber (sample phase,
fig. 5, part A). When the rat pressed the lever, it was retracted and a magazine was
illuminated, but no food pellet was delivered. When the rat made a nose poke into the
magazine (fig. 5, part B), the magazine light was turned off and both levers were inserted
(choice phase). Pressing of the non-sample lever was reinforced with the delivery of a food
pellet into the illuminated magazine (fig. 5, part C, left). If the rat pressed the sample lever,
the house light was turned off for 5 s (fig. 5, part C, right). After a 5-s period, a new cue lever
was inserted. If a rat did not press a cue lever (omission 1) or one of the choice levers
(omission 2), the house light was turned off for 5 s and a new sample lever was inserted after
a 5-s interval. After the rats had been trained for 10 days in the task (> 85 % correct
responses), delays (0, 1, 2, 4, 8 and 16 s) before inserting the choice levers were included. All
delays were used in each session of the DNMTP task in a random order (about10 trials/delay).
The training (20-30 minutes/day; 2-3 days/week) continued for four months (36 training days)
before the first group was operated.
Testing: Detailed testing paradigms can be found in publications I - III. The variables used in
the data analysis were the percentage of overall correct responses (correct responses / (correct
+ incorrect responses)* 100 %), the percentage of correct responses for each delay, the
percentage of omissions (omitted trials / all trials)* 100 %), and the latencies for sample
press, nose pokes and food collection (table 8).
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Fig. 5. The delayed non-matching to position task. Part A represents the first phase of one
trial of the DNMTP task. During the sample phase, one of the levers is presented into the
chamber, and a rat pushes it to start the next phase. Part B represents the second phase, the
delay phase, during which the rats are actively poking the magazine door. During this phase,
the rat is supposed to “keep in mind” the next choice. Part C represents the last phase, the
choice phase, which begins after the first nose poke into the magazine door after the delay (0,
1, 2, 4, 8 or 16 s in a random order). Both levers are presented into the chamber, and the rat
has to choose the lever it did not push before in order to get a reward pellet. If it makes a
correct choice and pushes the choice lever, the magazine light is turned on, and the dispenser
provides a reward pellet with a typical clicking sound. The rat has 5 s to eat his reward before
the next trial begins. However, if it chooses the sample lever again, no reward is provided and
the chamber light is turned of for another 5 s as a mark for incorrect response. A new sample
phase begins automatically after 5 s.
Click
Sample phase Delay phase
Choice phase
IncorrectCorrect
A B
C
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Table 8. DNMTP task parameters with explanations.
Measured parameter Estimated behavioral variable
Percentage of correct responses Overall accuracy
Delay dependency Decay of memory
Omissions Motivation, attention, motor activity
Latency of sample presses Motivation, attention, motor activity
Latency of nose pokes Motivation, attention, activity during delays
Latency of food collection Appetite, motivation, motor activity
4.4.2 Morris water maze (publications IV and V)
The Morris water maze (pool diameter 150 cm) was used to study spatial learning (Fig. 6, A).
A computer connected to an image analyser (HVS Image, Hampton, UK) monitored the swim
pattern (Fig. 6, B, C and D). The timing of the latency to find the submerged platform (10 x
10 cm) was started and ended by the experimenter. The following variables were used in the
data analysis: the daily escape distance values (IV and V), the number of counter crossings
during the spatial bias test and the number of rats that escaped to the platform during the first
trial of platform training (IV) (table 9).
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Fig. 6. Schematic drawing of the water maze pool. Part A: The cardinal points (North, East,
South, West) represent the starting locations. The starting points were selected in a semi-
random order (never from the same point as the previous start). Parts B C and D: Typical
swimming paths as seen on a computer monitor during the trials. Part B represents a typical
path in the beginning of the training (thigmotaxis i.e. swimming close to the wall). Part C
represents a typical search path of a rat that knows how to search for, but does not
know/remember the location of the hidden platform. Part D represents a typical search path of
a rat that is well aware of the rescue location.
PlatformA
C
North
East
South
West
DB
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Before testing, the rats were physically examined for external signs of disease (tumours,
infection, ulcers etc.). The rats were also tested for disabilities in swimming by introducing
one probe trial without platform in the pool. The starting locations on the pool rim (labelled
north, south, east, and west) were chosen arbitrarily (Fig. 6, A). The pool was divided into 4
quadrants (Southwest (SW), Southeast, Northwest, and Northeast (NE)) and 3 concentric
annuli of equal surface area. The water temperature was 22 ± 1.5 °C. The rats were placed in
the water with their nose pointing towards the wall, at one of the starting points. Those rats
that did not find the platform before the cut off time of 70 s were placed on the platform by
the experimenter. The rats were allowed to stay on the platform for 5 s. Every experiment
consisted of three daily trials, with a 30-s interval between trials. After the last training
session the rats were gently dried with a towel and placed back in their cages.
The water maze experiments are schematically described in Table 10. The training paradigms
and testing systems are described in detail in publications IV and V.
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Table 9. Water maze task parameters with explanations.
Measured parameter Estimated behavioural variable
Random navigation (first trial of a test) Initial navigation strategy
Swimming speed Motor function
Escape latency Navigation accuracy + swimming speed
Escape distance Navigation accuracy + strategy
Search bias (annulus crossings) Navigation accuracy
Table 10. The testing schemes of the water maze studies. In publication IV (part A), the
testing took place in only one water maze room. The escape performance of aged rats
receiving drugs was compared to that of the aged and young control groups receiving NaCl.
In publication V (part B), the rats were first pre-trained with either hidden or visible
platforms, and then tested in the same or different water maze room. Again, the escape
performance of aged rats receiving drugs was compared to that of the aged and young control
groups receiving NaCl. Abbreviations: Exp = experiment, D = the stage has both drug groups
and NaCl groups, Hidden = platform is hidden below the water surface, N = the stage has
only NaCl groups, Visible = platform has a clearly visible sign.
A. (Publication IV)
ROOM 1
Testing
Exp 1 Hidden D
Exp 2 Hidden D
Exp 3 Hidden D
Exp 4 Hidden D
B. (Publication V)
ROOM 1 ROOM 2
Pre-training Testing Testing
Exp 1 Hidden N Hidden D
Exp 2 Hidden N Hidden D
Exp 3 Visible N Hidden D
Exp 4 Hidden N Hidden D
Exp 5 Hidden D Hidden N
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4.5 HISTOLOGY
In publications I and II, the rats were decapitated one week after the completion of testing.
The brains were removed and the brain area containing the infusion site was placed into 4 %
formalin in 0.1 M phosphate-buffered saline for 24 h. In publication III, the rats were
euthanized with an overdose of chloral hydrate and perfused through the heart with 0.9 %
saline followed by 4 % formalin in 0.1 M phosphate-buffered saline. The brains were
removed and immersed in 4 % formalin in 0.1 M phosphate-buffered saline until sectioning.
After fixation, serial coronal sections (60 µm) were cut and stained with cresyl violet to
determine whether the cannulae had been correctly placed into the lateral ventricle (I and II)
or the dlFC and dmPFC (III)
4.6 STATISTICS
Statistical analyses were made using SPSS/PC+ software. Analysis of variance (ANOVA) for
repeated measures and Student’s t-test were used to analyse the behavioural parameters of the
DNMTP task (I-III). Before the ANOVA, the distribution of the data was normalized. The
data for the percentage of correct responses and of omissions were transformed using the
arcsin transformation, and the data for latencies were transformed using logarithmic
transformation. A oneway-ANOVA followed by Duncan’s post hoc multiple group
comparisons was used to measure the effects of the drug treatments on water maze acquisition
(IV-V). A twoway-ANOVA was used to assess the interactions of THA and DCS treatments
on water maze escape distance in the aged rats. The proportion of the rats that found / failed
to find the escape platform on the first trial was analyzed with a chi-square test. Values of P <
0.05 were considered significant. Methods for statistical analyses are described in detail in
publications I-V.
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5. RESULTS
5.1 DNMTP TASKS
Table 11. The effects of muscarinic antagonists and CPP (i.c.v.) on DNMTP task performance.
Abbreviations: METHO = methoctramine, PIRENZ = pirenzepine, SCOP = scopolamine, 0 = data not
available, − = no effect (P > 0.05), + = significant effect, ↑ = increasing effect, ↓ = decreasing effect, *
= P < 0.05, ** P < 0.005.
SCOP 3 µg SCOP 10 µg
Choice accuracy ↓ * −
Delay dependency − −
Omissions (%) − ↑ *
Latency of sample press (s) − ↑ *
Latency of nose poke (s) − −
Latency of food collection (s) − −
PIRENZ 10 µg PIRENZ 30 µg
Choice accuracy − ↓ *
Delay dependency − −
Omissions (%) − −
Latency of sample press (s) ↑ * ↑ *
Latency of nose poke (s) − −
Latency of food collection (s) − −
METHO 2 µg METHO 5 µg METHO 20
µg
Choice accuracy ↑(longest
delays)
− −
Delay dependence (+) P = 0.058 − −
Omissions (%) − − −
Latency of sample press (s) − − −
Latency of nose poke (s) − − −
Latency of food collection (s) − − −
CPP 0.1µg CPP 0.3 µg
Choice accuracy − ↓ *
Delay dependence − −
Omissions (%) − ↑ *
Latency of sample press (s) − ↑ *
Latency of nose poke (s) ↓ * 0
Latency of food collection (s) − 0
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5.1.1 The effects of scopolamine, pirenzepine, methoctramine and CPP (i.c.v.) on DNMTP
task performance (Publications I and II).
These tests were made to investigate whether the effects of central administration of
muscarinic and NMDA receptor antagonists on task performanced is mnemonic (delay-
dependent change in performance accuracy) or non-mnemonic (delay-independent change in
performance accuracy or changes in other variables) in nature. Table 11 summarises the
results.
Scopolamine 3 µg decreased choice accuracy, but the higher 10 µg dose did not significantly
affect the choice accuracy (I: results p. 131 and Fig. 1, top left). Scopolamine 10 µg increased
the percentage of omissions during the sample phase, but scopolamine 3 µg had no effect on
the omissions. (I: results p. 131 and table 1). Scopolamine 3 or 10 µg had no effect on the
sample press latency (I: results p. 131 and table 1) nose poke or food collection.
Pirenzepine 30 µg decreased choice accuracy, but the lower 10 µg dose had no effect on
choice accuracy (I: results p. 131 and Fig. 1, top right). Pirenzepine did not significantly
change the percentage of omissions but increased the latency to sample press (I: results p.
131, 132 and table 1).
Methoctramine, 2, 5 and 20 µg, had no significant treatment effect, but the delay by treatment
interaction was almost significant (I: results p. 132, Fig. 1, bottom left and right). A
comparison of the effects of methoctramine, 2, 5, and 20 µg, on choice accuracy at different
delays revealed that the lowest dose improved accuracy at the longest delays, with the effect
reaching significance at the 16-s delay (I: results p. 132). At the lowest dose, 2 µg, the
variances did not differ significantly between the delays, thus speaking against a possible
“bottom effect” behind the effect (I: results p. 132) (“bottom effect” means that statistic
results may be biased, if the variance of the choice accuracy is lower in the longer than
shorter delays). In addition, if the real effect of a drug is an impairment of choice accuracy in
the DNMTP task, the result might not become statistically significant, because the
performance has already reached its limit, i.e. performance is at a chance level. This separate
analysis was added, because one of the referees suggested that the bottom effect might
explain the result). Methoctramine, 5 and 20 µg, had no effect on choice accuracy at any
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delays. Methoctramine, 2, 5 and 20 µg, did not affect omissions or latency to sample press (I:
results p. 132, table 1).
CPP 0.1 had no effect on choice accuracy (II: results p. 10 and Fig. 1C), the percentage of
omissions or the latency of sample press but decreased the latency of nosepokes (II: results p.
10 and table 1). CPP 0.3 µg markedly and delay-independently reduced the choice accuracy
(II: results p. 10 and Fig. 1D). Furthermore, CPP 0.3 µg increased omissions and the latency
of sample press (II: results p. 10 and table 1).
5.1.2 The effects of combined i.c.v. administration of scopolamine, pirenzepine and CPP on
DNMTP task performance (Publications I and II).
Table 12. The effects of combined i.c.v. administration of muscarinic antagonists and CPP on
DNMTP task performance. Abbreviations: METHO = methoctramine, PIRENZ =
pirenzepine, SCOP = scopolamine, 0 = data not available, − = no effect (P > 0.05), + =
significant effect, ↑ = increasing effect, ↓ = decreasing effect, * = P < 0.05, ** P < 0.005.
CPP 0.03 µg SCOP 1 µg CPP 0.03 µg + SCOP 1 µg
Choice accuracy − − −
Delay dependence − − −
Omissions (%) − − ↑ **
Latency of sample press (s) − − ↑ **
Latency of nose poke (s) − − ↑ **
Latency of food collection (s) − − -
CPP 0.03 µg CPP 0.03 µg + PIRENZ 10 µg
Choice accuracy − −
Delay dependence − −
Omissions (%) ↓ * −
Latency of sample press (s) − −
Latency of nose poke (s) − −
Latency of food collection (s) − −
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These experiments were conducted to investigate whether the effects of combined central
administration of muscarinic and NMDA receptor antagonists at subthreshold doses were
mnemonic (delay-dependent change in performance accuracy) or non-mnemonic (delay-
independent change in performance accuracy or changes in other variables) in nature. Table
12 summarises the DNMTP results from i.c.v infusions of muscarinic antagonists and CPP.
Administration of CPP 0.03 µg or scopolamine 1µg alone had no effect on the choice
accuracy (II: results p. 10 and Fig. 1F), the percentage of omissions or the latency of sample
press (II: results p. 10 and table I). Simultaneous administration of these sub-threshold doses
of CPP 0.03 µg and scopolamine 1µg had no effect on the choice accuracy (II: results p. 10
and Fig. 1F) but robustly increased the omissions, the latency of sample press and increased
the latency of nose pokes (II: results p. 10 and table 1).
Simultaneous administration of CPP 0.03 µg and pirenzepine 10 µg had no effect on choice
accuracy (II: results p. 11 and Fig 1G), the omissions or the latency of sample press. In this
test, CPP 0.03 µg on its own slightly decreased the omissions (II: results p. 11 and table 1).
None of the treatments significantly affected the latency of food collection (II: table 1).
5.1.3 The effects of CPP and scopolamine (i.c.) on DNMTP task performance in dmPFC or
dlFC (Publication III).
These tests were made to investigate whether administration of the NMDA receptor
antagonist CPP directly into the dmPFC have mnemonic or non-mnemonic effects on
performance. These drug effects were compared to the effects of scopolamine, which have
been reported to cause a non-mnemonic performance deficit in the DNMTP task (Dunnett et
al., 1990; Herremans et al., 1996). As a control area, we used the dorsolateral frontal cortex
that according to the literature is not likely to be important in the regulation of WM (Dunnett,
1990; Wortwein et al., 1994).
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Table 6 summarises the DNMTP results from i.c. infusions of CPP and scopolamine into the
dmPFC or dlFC.
Table 6. The effects of CPP and scopolamine on DNMTP task performance in the dmPFC or
DlFC. Abbreviations: METHO = methoctramine, PIRENZ = pirenzepine, SCOP =
scopolamine, 0 = not tested, − = no effect (P > 0.05), + = significant effect, ↑ = increasing
effect, ↓ = decreasing effect, * = P < 0.05, ** P < 0.005.
CPP 0.01 and CPP 0.03 µg dmPFC DlFC
Choice accuracy − 0
Delay dependence − 0
Omissions (%) ↑ 0
Latency of sample press (s) ↑ 0
Latency of nose poke (s) ↑ (CPP 0.01) 0
CPP 0.1 µg dmPFC DlFC
Choice accuracy − −
Delay dependence +* −
Omissions (%) ↑ −
Latency of sample press (s) ↑ −
Latency of nose poke (s) ↑ −
CPP 0.3 µg dmPFC DlFC
Choice accuracy ↓ −
Delay dependence − −
Omissions (%) − −
Latency of sample press (s) ↑ ↑
Latency of nose poke (s) ↑ ↑
Scopolamine 10 µg dmPFC DlFC
Choice accuracy − −
Delay dependence − −
Omissions (%) − −
Latency of sample press (s) ↑ −
Latency of nose poke (s) ↑ −
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In the dmPFC, both CPP 0.01 and CPP 0.03 µg increased the percentage of omissions and the
latency of sample press (III: results p. 244, 246 and table 1) but had no effect on choice
accuracy (III: results p. 246 and Fig. 1A). CPP 0.01 also increased the latency of nose pokes
(III: table 1)
In the dmPFC, the main effect of CPP 0.1 µg on choice accuracy was non-significant, though
there was a significant drug by delay interaction. The decrease in choice accuracy was
significant at 1 and 2 s delays, indicating a delay-dependent defect in performance (III: results
p. 246 and Fig. 1B). The treatment also increased omissions and the latencies of sample press
and nose poke (III: results p. 246 and table 1). The highest CPP dose 0.3 µg decreased the
choice accuracy delay-independently (III: results p. 246 and Fig. 1C) and increased the
omissions and the latencies of sample press and nose poke in the dmPFC (III: results p. 246
and table 1).
Scopolamine 10 µg in the dmPFC had no effect on choice accuracy or omissions (III: results
p. 246, Fig 1C and table 1) but increased the latencies of sample press and nose poke (III:
results p. 246 and table 1).
In the dlFC, both CPP and scopolamine had markedly different effect profiles when compared
to the effects in the dmPFC. CPP 0.1 µg had no effect on the choice accuracy, omissions or
latencies of sample press and nose poke in the dlFC (III: results p. 246, Fig 1D and table 1).
CPP 0.3 µg had no effect on the choice accuracy or omissions (III: results p. 246, Fig 1D and
table 1) but increased the latency of sample press and nose poke (III: results p. 246, Fig 1D
and table 1).
Scopolamine 10 µg had no effect on the choice accuracy, omissions, sample press or nose
pokes in the dlFC (III: results p. 246, Fig 1D and table 1).
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5.1.3 Histology
Examination with light microscope revealed that all the cannulae of the rats included in the
analysis had been correctly placed into the left or right ventricle (I and II). In addition, the
cannulae targeted into the dmPFC and dlFC had also been correctly placed (III). All the
dmPFC cannulae had been placed between the coordinates 3.7 mm and 4.2 mm anterior to the
bregma (Paxinos and Watson, 1986), i.e. in the rostral part of the dmPFC (III).
5.2 WATERMAZE TASKS
5.2.1 The effects THA and DCS (i.p.) on spatial navigation of aged rats ( IV).
This study was designed to elucidate whether combined treatment with a cholinesterase
inhibitor, THA, and a positive modulator of the NMDA receptor, DCS, is more effective than
treatment with either drug on its own in stimulating spatial navigation in aged rats. Table 14
presents the testing scheme, and Table 15 summarises the water maze results from i.p.
infusions of THA and DCS.
Table 14.Schematic representation of the water maze testing procedure (IV).
                  WATER MAZE  1
Training
days
Platfor
m
Administration
Exp 1 5 hidden drugs before training
Exp 2 5 hidden drugs before training
Exp 3 5 hidden drugs before training
Exp 4 4 hidden drugs after training
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Table 15. The effects of THA and DCS (i.p.) on the performance of aged rats in the water
maze (compared to aged controls).
Drug groups
(mg/kg)
Initial search
strategy
Escape
distance
Spatial bias
after testing
THA 0.3 0 0 0
THA 1 0 0 0
THA 3 0 ↓ 0
DCS 1 0 0 0
DCS 3 0 0 0
DCS 10 0 ↓ ↑
THA 0.3 + DCS 1 0 0 0
THA 1 + DCS 3 0 ↓ ↑
THA 3 + DCS 10 0 ↓ ↑
THA 3 + DCS 10
(post training)
- 0 0
Abbreviations; 0 = no effect,  ↓ = drug decreased escape distance, ↑ = drug increased number
of annulus  (platform area) crossings during probe trial after training, -  =  not tested.
In the first study, we used 5 groups of 8 rats: young and aged controls, aged THA 3 mg/kg,
aged DCS 10 mg/kg and aged THA 3 mg/kg + DCS 10mg/kg. The proportion of rats that
found the platform during the first trial of the first day did not differ between the groups,
suggesting that the initial search strategies did not differ between the groups (IV: results p. 17
and table 1A). THA 3 mg/kg or DCS10 mg/kg alone were equally effective in decreasing the
escape distance of aged rats (IV: results p. 17 and Fig. 1A). A combination of THA 3 mg/kg
and DCS10 mg/kg was no more effective in decreasing the escape distance than single
treatments alone (IV: Fig. 1A). Furthermore, we found no interaction between the two
treatments (DCS10 mg/kg x THA 3 mg/kg; IV: results, p. 17). During the spatial probe trial,
aged rats that were treated with DCS10 mg/kg or THA 3 mg/kg + DCS 10 mg/kg during the
training phase made more correct platform crossings than did the other groups of aged rats
(IV: results p. 17 and table 1B). Aged rats treated with either DCS 10 mg/kg alone or with the
combination of DCS10 mg/kg and THA 3 mg/kg had as strong spatial bias towards the target
quadrant as the young control rats. In contrast, THA 3 mg/kg alone had no effect on the
spatial bias of aged rats (IV: results p. 17 and table 1B).
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In the second study, we used 5 groups of 9 rats: young and aged controls, aged THA 1 mg/kg,
aged DCS 3 mg/kg and aged THA 1 mg/kg + 3 mg/kg. Again, we found that the proportion of
rats that found the platform during the first trial of the first day did not differ between the
groups (IV: results p. 17 and table 1A). In aged rats, THA 1 mg/kg or DCS 3 mg/kg on their
own had no effect on escape distance over days 1 to 5 (Fig 1B) or spatial bias in the probe test
(table 1B). However, the ANOVA revealed a significant interaction between these treatments:
aged rats treated with the combination of THA 1 mg/kg and DCS 3 mg/kg had the shortest
escape distance when compared to the other aged groups (IV: results p. 18 and Fig. 1B). THA
1 mg/kg + DCS 3 mg/kg also interacted to increase the spatial search bias of aged rats (IV:
results p. 18 and table 1B) in the final probe test.
In the third study, we used 4 groups of 9 aged rats: controls, THA 1 mg/kg, DCS 1 mg/kg and
THA 0.3 mg/kg + DCS 1 mg/kg. The proportion of rats that found the platform during the
first trial of the first day did not differ between the groups (IV: results p. 18 and table 1A).
THA 0.3 mg/kg or DCS 1 mg/kg plus their combination had no effect on escape distance or
spatial bias (IV: results p. 18, Fig 1C and table 1B).
In the fourth study that examined the effect of drugs administered after daily training sessions,
we used 5 groups of 8 rats: young controls, aged controls, aged THA 3 mg/kg, aged DCS 10
mg/kg and aged THA 3 mg/kg + DCS 10 mg/kg. The proportion of rats that found the
platform during the first trial of the first day did not differ between the groups (IV: results p.
18 and table 1A). The results revealed that all aged rats were worse than the young rats in
finding the hidden platform during the training days 1-5 (IV: results p. 18 and Fig 1D).
Administration of single or combined DCS 10 mg/kg or THA 3 mg/kg after daily training
trials failed to decrease escape distance or increase spatial bias.
5.2.2 The effects of pre-training on the improved spatial navigation of aged rats induced by
THA and DCS (V).
In this study, we examined the effects of pretraining on the previously observed improvement
in spatial navigation of aged rats induced by THA and DCS. Pre-training took place under
different conditions and included pre-training for a non-spatial escape strategy. We also
investigated whether the pre-training might had any effect on the age-related spatial
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navigation deficit itself.
Table 16. Schematic representation of the water maze testing procedure (IV).
WATER MAZE 1 WATER MAZE 2
Pre-training Pause Testing -
Exp 1 5 days hidden placebo 30 days 5 days hidden drugs -
Exp 2 5 days hidden placebo 30 days 5 days hidden drugs -
Exp 3 3 days visible placebo 30 days 5 days hidden drugs -
                  WATER MAZE 1 WATER MAZE 2
Pre-training Pause room change  Testing
Exp 4 8 days hidden placebo 2 days " 6 days hidden drugs
Exp 5 6 days hidden drugs 2 days " 5 days hidden placebo
Summary of the results. The alleviating effect of both D-cycloserine and
tetrahydroaminoacridine (separately or in combination) on the age-related defect in escape
performance disappeared after pre-training under different conditions, including pre-training
for a non-spatial escape strategy. The spatial navigation defect in aged rats still remained after
the pre-training procedures. (see V p. 315 and 316 for figures)
In experiment 1 (V: Fig. 1A), we used 5 groups of 10 rats: young and aged controls, aged
THA 3 mg/kg, aged DCS 10 mg/kg and aged THA 3 mg/kg + DCS 10 mg/kg. During the first
five-day training period, with no drug treatments, all the groups of aged rats were worse than
young controls in finding the hidden platform in the SW quadrant (V: results p. 316 and Fig.
1A, left plot). In the second training period occurring after a break of 1 month, none of the
single or combined treatments improved the performance of the aged rats in locating the
hidden platform in the SW quadrant (V: results p. 316 and Fig. 1A, right plot).
In experiment 2 (V: Fig. 1B), we used 5 groups of 10 rats: young and aged controls, aged
THA 3 mg/kg, aged DCS 10 mg/kg and aged THA 3 mg/kg + DCS 10 mg/kg. Again, during
the first training period, with no drug treatments, all groups of aged rats were worse than
young controls in finding the hidden platform in the SW quadrant (V: results p. 317 and Fig.
1B, left plot). In the second training period, drug treatments failed to alleviate the age-related
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impairment of learning, as none of the single or combined treatments improved the aged rats
to find the hidden platform in the NE quadrant (V: results p. 317 and Fig. 1B, right plot).
In experiment 3 (V: Fig. 1C), we used 5 groups of 10 rats: young and aged controls, aged
THA 3 mg/kg, aged DCS 10 mg/kg and aged THA 3 mg/kg + DCS 10 mg/kg. In the first
stage of training with a visible platform, no age-related defect was found (V: results p. 317
and Fig. 1C, left plot). In the second stage with a hidden platform, the aged rats were more
impaired than the young controls. None of the single or combined drug treatments alleviated
this impairment of the aged rats (V: results p. 317 and Fig. 1C, right plot).
In experiment 4 (V: Fig. 2 A), we used 4 groups of 12 rats: young and aged controls, aged
THA 3 mg/kg and aged DCS 10 mg/kg. During the first stage (hidden platform), the aged rats
were more impaired than the young controls. At this stage, the rats received no drug
treatments, and no difference was observed in the escape distance among different groups of
the aged rats (V: results p. 317 and Fig. 2 A, left plot). The second stage (hidden platform)
was conducted in a novel testing room after a break of two days. Again, the aged rats were
more impaired than the young controls. The drug treatments failed to alleviate the impaired
performance of the aged rats (V: results p. 317 and Fig. 2 A, right plot).
In experiment 5 (V: Fig. 2 B), we used 3 groups of 12 aged rats: controls, aged THA 3 mg/kg
and aged DCS 10 mg/kg. In the first stage of training with a hidden platform, the groups
treated with THA and DCS had shorter escape distance values than the aged controls (V:
results p. 317 and Fig. 2 B, left plot). During the second stage conducted in a novel testing
room (hidden platform), the rats received no drug injections. Those groups that had been
treated with THA and DCS during the first stage performed no better than those previously
treated with the vehicle (V: results p. 317 and Fig. 2 B, right plot).
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6. DISCUSSION
6.1 METHODOLOGICAL CONSIDERATIONS
6.1.1 DNMTP task.
Advantages. The strength of the DNMTP task is that the mnemonic specificity of the effects
can be determined against a baseline forgetting curve. A mnemonic effect is reflected as a
delay-dependent change in the memory decay curve, whereas a delay-independent effect
suggests additional disturbance of non-mnemonic processes such as attentional, motivational
or sensorimotor processes. The task also allows for measuring additional non-mnemonic
performance parameters, such as motivation and motor activity, thus making this task suitable
for examining the specificity of working memory effects, although attention and arousal
processes are difficult to differentiate from motor activity. In addition, the DNMTP task is
automated, which helps eliminate the introduction of any subjective component to the testing.
Furthermore, each individual is compared to itself, which adds to the statistical power and
allows for the use of fewer subjects.
Critique 1. Despite the advantages, the DNMTP task is not perfect. Today it is known that
rats are able to adopt a biased response strategy that leads to high level of accuracy and high
amount of omissions (Dunnett, 1993). In such a case, the rat only responds to one lever, and
ignores those trials that begin by presenting the other lever. Our DNMTP analysis programme
did not measure such bias. However, in the case of methoctramine, which improved
performance accuracy in the longest delays, there was no increase in the omissions, thus
speaking against any significant beneficial response bias. On the other hand, if pressing one
of the levers during the choice phase is favoured and the responses during the sample phase
are normal, the acquired bias leads to decreased accuracy. Although the accuracy disrupting
bias could not be analysed with our programme, our DNMTP task measured other parameters
that covered a variety of non-mnemonic performance deficits.
Critique 2. During statistical analysis, such phenomena as ceiling (roof) and floor (bottom)
65
effects can cause problems. Because the accuracy is measured on a percentage scale, the
variance of performance accuracy may be lower in the shortest or longest delaysthan that in
the medium-length delays. Because of this possibility, we used arcsin correction in the
analysis, which converts the results from a percentage into a logarithmic scale, thus correcting
the statistical problem. However, if the accuracy is "too high" across all the delays, it is more
difficult to improve the performance accuracy than if the accuracy level is modest. Similarly,
if the performance accuracy at the longest delays is already at the chance level, it is
impossible to further decrease the accuracy. This behavioural aspect of floor and ceiling
effects cannot be corrected by using logarithmic corrections in statistical analysis. In our
studies, the behavioural, but not the statistical, bottom effect may have masked some of the
accuracy deficits at the longest delays. Furthermore, variation in the basal performance
accuracy, as well as strain differences and differences in task details, make it difficult to
directly compare our results with that from other studies using operant D(N)MTP tasks.
Critique 3. Recently, serious criticism has been raised against the validity of operant
D(N)MTP tasks as working memory tasks. Critical groups have shown that the rats are able to
use several types of positional strategies (Chudasama and Muir, 1997; Herremans et al.,
1996). Originally, it was suggested by Dunnett that active nose poking behaviour acts as a
distracter and prevents the rats from using a positional (mediating) strategy during the delay
phase (Chudasama and Muir, 1997; Dunnett, 1985). The critical groups suggest that rats do
not use their working memory during the delay, but a strategy that is a reflection of motor
rather than mnemonic performance. The use of positional strategies could not be monitored in
our studies. However, although the use of positional strategies is well documented, there is
one property in the DNMTP and DMTP tasks indicating that working memory processes, and
not only mediating strategies, account for the performance accuracy. Namely, a phenomenon
called proactive interference has an influence on the performance accuracy in delayed operant
tasks (Dunnett et al., 1990; Hampson et al., 1998). Proactive interference means that the
memory of the preceding trial has an effect on the performance accuracy in the ongoing trial.
If the performance accuracy only reflects mediating strategies, then proactive interference
should have no significant effect on it. Interestingly, two tasks that do not allow use of any
mediating strategies have recently been developed: the delayed conditional discrimination
task (DCD) developed by Herremans and Hizen (1997) and the discrete paired-trial T-maze
task developed by Aultman and Moghaddam (2001). In the DCD task, memory decay occurs
66
within 20 s (log d of accuracy around 0.8 at the longest 20 s delay), and in the T-maze task
the memory decays within 40 s (accuracy around 60% at the longest 40 s delay). In our
DNMTP task the performance was near chance level within 16 s. This suggests that the
accuracy in our task did not exceed the working memory capacity of rodents, which in turn
increases the probability that the memory curve in our task reflects working memory
processes. Therefore, it can be concluded that the benefit from using the mediating strategies
was minimal, when compared to the use of “pure” working memory only. In addition, the
delay-independent effect of scopolamine found in our study is similar to delay-independent
effects reported in studies using both DCD and T-maze tasks (Aultman and Moghaddam,
2001; Herremans et al., 1997). These results indicate that our DNMTP task is able to provide
reliable non-mnemonic effects with respect to the memory decay curve.
Attention and DNMTP task. A working memory task such as the DNMTP requires the rat to
focus on "keeping in mind" the location of a hidden lever. Yet, if the rat does not focus on
what it is supposed to do during the task, the monitored non-mnemonic performance deficit
may be due to disruption of several aspects of behaviour that are not easily differentiated. For
example, attentional deficits may cause similar changes in such task parameters as defects in
motivation, sensorimotor processes, arousal or impulsivity/restlessness. Behaviourally,
systemic administration of muscarinic and NMDA antagonists disrupt performance in tasks
modelling sustained attention in rodents (Robbins, 2002; Sarter et al., 2001), thus suggesting
that attentional problems may contribute to the performance deficit also observed in our
study. However, because the reported drug effects have not been specific to attentional
processes, it is likely that non-specific effects on sensorimotor or motivational processes may
also contribute to the performance deficit in so-called attentional tasks (Robbins, 2002; Sarter
et al., 2001). For example, scopolamine has been shown to both decrease choice performance
accuracy in the 5-choice serial reaction time task for rodents, as well as disrupt overall task
performance (Jäkälä et al., 1992; Ruotsalainen et al., 2000). In addition, systemic
administration of dizocilpine, an NMDA receptor antagonist, not only impairs choice
performance accuracy in this task but also induces additional performance deficits, such as
increased premature responses (Grottick and Higgins, 2000). Furthermore, Both scopolamine
and the NMDA antagonist MK-801 have been shown to disrupt overall performance in
Spatial signal detection task (Presburger and Robinson, 1997).
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It is of special relevance to our study using local prefrontal microinjections that lesioning of
the mPFC impairs sustained attention as assessed in the 5-choice serial reaction time task,
although additional performance deficits not specific to attention may also occur (Robbins,
2002; Sarter et al., 2001). In addition, scopolamine has been reported to induce attentional
deficit when administered locally into the mPFC, although at the antero-dorsal part of the
PFC, non-specific effects were also present (Robbins, 2002).
Our analysis programme lacked the ability to monitor performance changes as a function of
test time. Therefore, possible changes in activity or choice performance accuracy during the
course of the testing session, which could reflect changes in arousal or motivation, could not
be detected. In future studies, more information could be gained if the analysis included such
modifications as separate response latencies for correct vs incorrect choices, delay activity
before correct vs incorrect responses, and measurement of response bias.
6.1.2 Water maze task
In order to learn how to complete a water maze task successfully, a rat must also acquire non-
spatial components of learning such as swimming, searching for and climbing onto a hidden
platform and “appreciating” that the platform represents rescue from the tank, and to abandon
the natural first strategy to search for an escape in the pool wall (thigmotaxis). Consequently,
if a drug facilitates acquisition of non-spatial components of learning, then these already
acquired abilities are not likely to be further improved in the new environment. Earlier studies
have shown that non-spatial pre-training in a different water maze alleviates or even prevents
the learning deficit caused by the NMDA receptor antagonist, (+/-)-2-amino-5-
phosphonopentanoic acid (AP-5) (Cain et al., 1996). Since it is possible that THA and DCS
enhance the spatial navigation performance of aged rats by improving non-spatial components
of learning, such as sensorimotor skills or motivation, we examined the influence of pre-
training on the effects of THA and DCS on spatial navigation in the water maze. Our
hypothesis was that if a drug primarily improves spatial memory and learning, its effects
should still be significant after pre-training for a non-spatial cue strategy, spatial training in a
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different environment or reversal of the relationship between the extra maze cues and the
escape platform.
Pre-training of the rats tests more reliably than the original version of the water maze task
whether non-mnemonic aspects of spatial navigation learning are affected. Still, the
traditional version of water maze task also allows for controlling whether the rats have
acquired a true place strategy, i.e. ability to use extra maze cues to navigate onto the escape
platform. For example, impaired navigation onto a visible platform may be an indication of
additional disturbance of non-mnemonic processes such as perception, motivation or
sensorimotor coordination. In addition, using a probe trial at the end of an experiment reveals
whether the rats have acquired a spatial bias, i.e. tendency to swim across and in close
vicinity to the area that previously contained the hidden platform. Development of a spatial
bias reveals that the rat has learned the location of the hidden platform correctly, uses place
strategy for navigation and is motivated to search for it. The development of a spatial bias
gives more specific information about navigation learning than latency to find the hidden
platform, since swimming speed can be affected by drug treatments. The aged rats we used
were large and over-weight, which made them slower swimmers than the young controls. In
order to correct for the effect of group difference in the swimming speed, we used escape
distance as the parameter for navigation learning, instead of escape latency. Nevertheless, it is
possible that the greater weight leading to decreased swimming speed and overall clumsiness
could have introduced a confounding factor, which may in part explain the parallel learning
curves described in publication IV.
6.2 SPATIAL WORKING MEMORY
6.2.1 The effect of centrally administered muscarinic antagonists is not specific for working
memory.
Effective doses of scopolamine and pirenzepine caused delay-independent deficits in the
DNMTP task, suggesting that both drugs do not have a specific effect on working memory,
but instead may cause attentional, motor or other non-specific behavioural disturbances.
Scopolamine (10 µg) decreased motor activity, as reflected by the increased sample press
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latency, and caused additional disturbances in attention or motivation by increasing omissions
during the sample phase. Pirenzepine (10 and 30 µg) caused a milder effect than scopolamine,
since it only decreased motor activity during the sample phase, though it had no additional
effects on motivation. Neither scopolamine (3 and 10 µg) nor pirenzepine (10 and 30 µg)
affected appetite or motor activity during delays, as reflected by food collection and nose
poke latencies, respectively.
Scopolamine. The non-mnemonic effects of scopolamine in our study are in agreement with a
number of studies using delayed response paradigms (Andrews et al., 1994; Chudasama and
Muir, 1997; Han et al., 2000; Stanhope et al., 1995). It is likely that disruption of attentional
and other non-mnemonic processes caused by scopolamine is reflected as delay-independent
performance deficit in delayed tasks (Jones and Higgins, 1995; Jäkälä et al., 1992; Phillips et
al., 2000; Ruotsalainen et al., 2000). Whether the behavioural effects of scopolamine are
mediated by peripheral or central muscarinic receptors has usually been investigated by using
methyl scopolamine, a compound that should not pass the blood-brain-barrier, as a
comparison drug. Like scopolamine, methyl scopolamine decreases performance accuracy in
both DMTP and DNMTP tasks, suggesting that the effects of scopolamine may be mediated
through peripheral receptors (Andrews et al., 1994; Buxton et al., 1994). However, there is
evidence that methyl scopolamine is able to enter the brain despite its highly polarised nature,
and therefore its behavioural effects cannot be directly attributed to peripheral receptors
(Andrews et al., 1994; Moore et al., 1992). Our results show that the i.c.v. administration of
scopolamine decreases performance accuracy, thus linking the delay-independent disruption
of choice accuracy in the DNMTP task directly to central receptors. In addition, non-selective
blockade of central muscarinic receptors also disturbed motivation and motor activity,
suggesting that centrally acting non-selective muscarinic antagonists produce a robust
disruption of attentional, motor or other non-memory specific processes.
Pirenzepine. Our results suggest that the M1 receptors (high affinity to pirenzepine) mediate
the disrupting effects of scopolamine on performance accuracy, since the effect of 30 µg
pirenzepine was similar to that with 10 µg scopolamine. In our study, the potency ratio of
pirenzepine vs scopolamine was similar to the study of Hagan et al. (1987). In their study, 93
µg (209 nmoles) of pirenzepine disrupted learning in the Morris water-maze task as
effectively as 28.9 µg (72 nmoles) of scopolamine, suggesting that pirenzepine is
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approximately 3-fold weaker than scopolamine in disrupting spatial place navigation (Hagan
et al., 1987). Although the study of Hagan et al (1987) as well as a study by Hunter and
Roberts (1987) suggest that 30 µg of pirenzepine disrupts water-maze navigation without
additional disruption in performance, our results are not in line with that interpretation.
Instead, the present results suggest that pirenzepine may induce attentional or other non-
mnemonic disturbances; thus, it can be assumed that the water maze task used in previous
studies (Hagan et al., 1987; Hunter and Roberts, 1987) was probably not sufficiently
sensitive. Our results disagree with Andrews et al. (1994) who reported that i.c.v. pirenzepine
at doses of 3.2 – 32 µg disrupted DMTP performance delay-dependently, without additional
behavioural disturbances. Notably, in their study the basal performance accuracy was much
higher (75 % correct at 45 s delay) than in our study, making it possibly more resistant to
disruption than in our study. However, such differences can also be explained by the fact that
the DMTP and DNMTP are two different tasks that involve use of qualitatively different
conditional decision rules (Dunnett, ). Therefore, a direct comparison between the two tasks is
difficult.
Methoctramine. Our data showing that methoctramine 2 µg modestly improved choice
performance accuracy selectively at long delays agrees with previous evidence indicating that
treatment with muscarinic M2 receptor antagonists may enhance performance in tests used to
assess learning and memory performance. For example, administration of BIBN 99 (5,11-
dihydro-8-chloro-11-[[4-[3-[(2,2-dimethyl-1-oxopentyl)ethylamino]propyl]-1-
piperidinyl]acetyl]-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one), another muscarinic M2
receptor antagonist, enhanced acquisition of the water maze task in young rats subjected to
head trauma (Pike and Hamm, 1995) and in aged, cognitively impaired rats (Quirion et al.,
1995). BIBN 99 has been shown to increase ACh release in the cortex of aged rats, suggesting
that the effect of the drug on water-maze navigation is mediated via blockade of presynaptic
muscarinic M2 autoreceptors (Quirion et al., 1995). However, as explained above, it is
difficult to interpret the beneficial effects of drugs administered prior to daily water maze
testing simply in terms of improved learning and memory. Therefore, the present results are
important, since they reveal a genuine delay-dependent, although modest, improvement,
indicating an improvement in short-term memory per se. Interestingly, Packard et al. (1990)
showed that the administration of AF-DX 116 ([R,S]-11-[[2-[diethylamino)-methyl]-1-
piperidinyl]acetyl]-5,11-dihydro[2,3-b][1,4]-benzodiazepin-6-one), a muscarinic M2 receptor
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antagonist, stimulated memory consolidation in two different radial arm maze tasks.
Therefore, present and previous (Packard et al., 1990) data suggest that an M2 antagonist may
improve maintenance of short-term memory and consolidation of long-term reference
memory. The failure of higher doses of methoctramine to improve memory function may be
attributed to the loss of selectivity to M2 vs. muscarinic M1 receptors. Indeed, a recent study
by Ohno et al. (1995) described how only a dose of methoctramine high enough to block
muscarinic M1 receptors could impair three-panel runaway performance and that AF102B, a
muscarinic M1 receptor agonist, attenuated this impairment. Another potential explanation for
the failure of higher doses to improve memory functions is that higher doses of
methoctramine produce too robust an increase in synaptic ACh levels, thus disrupting the
physiological, phasic variation in the cholinergic signal transmission and introducing ‘noise’
to the system processing spatial short-term memory.
 6.2.2 Central administration of the NMDA receptor antagonist CPP is associated with several
non-mnemonic effects.
An effective dose of CPP (0.3 µg) caused a delay-independent decrease in correct responses,
suggesting that CPP induced disturbance of other processes than working memory per se. In
addition, CPP 0.3 µg disrupted sensory, motor or attentional functions as evidenced by
increasing omissions and latency to respond during the sample phase. CPP 0.1 µg increased
motor activity during delays, but had no effect on correct responses, motivation (omissions)
or motor activity during the sample phase. CPP (0.1 or 0.3 µg) did not significantly affect
motor activity during food collection, suggesting that CPP did not decrease general
motivation and appetite.
Our results are in agreement with previous studies reporting that CPP disrupts performance
accuracy independent of the delay. For example, Tan et al. showed that CPP (10 mg/kg)
caused a delay-independent impairment in a conditional discrimination task (Tan et al., 1989),
and Pontecorvo et al. (1991) showed that CPP (5 mg/kg) caused a delay-independent
impairment of performance accuracy in a non-spatial continuous non-matching to sample
task. However, our results disagree with Cole et al. (1993), who reported that CPP (10 mg/kg)
disrupted accuracy delay-dependently in Dunnet’s DMTP task. Again, the apparent
discrepancy could be explained by the difference in the non-matching vs matching
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behavioural paradigms, but it should be noted that a delay-independent deficit has been
reported with the DMTP task as well (Doyle et al., 1998). In addition, the study of Cole et al.
(1993) showed that performance accuracy was higher over all delays, (over 75 % correct in
30 s delay). It has been shown that if the performance accuracy is high during the longest
delays, the use of effective mediating strategies may also be higher, which makes it easier to
gain delay-dependent effects (Herremans, 1996). Furthermore, the Cole et al. study also found
additional disruption of motor activity, as reflected by the increased latency to respond and
the number of nose pokes. Therefore, both previous and our own data suggest that CPP
disrupts attentional and other non-memory-specific processes, thus causing secondary
disruption of working memory.
6.2.3 Combined central administration of CPP and either scopolamine or pirenzepine has no
specific effect on working memory.
Individual administration of CPP (0.03 µg) or scopolamine (0.1 µg) did not affect correct
responses or any of the other measured behavioural parameters, suggesting that these
parameters had no significant effect on motivation, motor activity or appetite. When these
sub-threshold doses of CPP and scopolamine were combined, the consequence was a clear
disruption of motivational processes and motor activity before and during the delays, though
correct responses remained intact. On the other hand, the combination of pirenzepine (10 µg)
with CPP (0.03 µg) did not affect any of the measured behavioural parameters, including
correct responses.
The main finding of this study was that the NMDA and muscarinic receptors conjointly
modulated non-mnemonic components of DNMTP task performance, but did not influence
working memory. This finding was not unexpected since extensive anatomical distribution
and the overall general nature of the two neurotransmitter systems in the brain suggest that
non-mnemonic effects would be anticipated to occur when muscarinic and NMDA receptors
are manipulated concurrently. In addition, antagonists of both the muscarinic and NMDA
receptors induce sensorimotor, attentional and other non-specific behavioural dysfunction in
animals and humans (Blokland, 1996; Broks et al., 1988; Cotman and Iversen, 1987; Dunne
and Hartley, 1986; Ebert and Kirch, 1998; Oranje et al., 2000). Our second finding was that
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pirenzepine was totally ineffective when combined with CPP, suggesting that the muscarinic
M1 receptors do not mediate the performance disrupting interaction with NMDA receptors.
This was quite unexpected, since pirenzepine on its own disrupted performance in our
DNMTP task delay-independently, suggesting that the M1 receptors probably mediate the
performance deficit caused by scopolamine. It is not likely that the doses of pirenzepine (10
µg) or CPP (0.03 µg) were too low, since pirenzepine (10 µg) on its own slightly increased
the latency of sample presses, and CPP (0.03 µg) disrupted performance when administered
with a subthreshold dose of scopolamine (0.1 µg). In addition, because we kept the rats drug-
free for two weeks before the last experiment to avoid tolerance, it is not likely that the rats
could have developed tolerance to the drug effect. Therefore, based on the antagonist affinity
profiles (table 7), it can be concluded that additional blockade of the non-M1 receptors,
possibly excluding the M5 and M2 receptors, is needed for the synergistic effect with an
NMDA receptor blockade.
Since the low doses of CPP and pirenzepine did not interact in regulating the performance of
rats in the DNMTP task, it could be possible that low doses of these drugs mediate
independent behavioural effects. In fact, low doses of NMDA antagonists are able to improve
performance in short-term memory tasks (Mondadori and Weiskrantz, 1993; Sharma and
Kulkarni, 1991). Moreover, NMDA antagonists have been reported to act as behavioural
stimulants and to cause anxiolytic effects (Cotman and Iversen, 1987). It is therefore possible
that there was no additive/synergistic effect by the combined blockade of NMDA and
muscarinic receptors, because the low doses of pirenzepine and CPP mediate counteracting
behavioural effects. However, a lack of effect with two sub-threshold doses is not sufficient
evidence to prove the existence of some form of counteracting process, and therefore this
explanation is only speculative.
In our experimental setup, it was possible to study the memory-specific effects separately
from non-specific effects. Other studies have also examined the interaction of muscarinic and
NMDA receptors in the regulation of learning and memory processes; however, these studies
lacked the ability to differentiate the non-mnemonic performance deficits from attentional or
sensorimotor effects. For example, in a study by Hlinak and Krejci sub-effective doses of
scopolamine and MK-801 produced short-term amnesia in an elevated plus maze task that
does not measure, for example, attentional aspects of performance (Hlinak and Krejci, 1998).
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Similarly, Ohno and Watanabe reported that scopolamine and MK-801 at sub-threshold doses
impair learning of inhibitory avoidance, which is a rather non-specific form of learning (Ohno
and Watanabe, 1996). Our study suggests that non-mnemonic performance deficits were
present in these studies, and probably significantly contributed to the results. Our study
revealed only a performance deficit of a non-mnemonic type, suggesting that working
memory is not the first process affected in the line of spatial information processing in the
CNS.
We also found that the performance accuracy in our DNMTP task is, to a certain extent,
resistant to attentional or motor performance deficit caused by combined treatment with
scopolamine and CPP. However, whether this is caused by the resistance of spatial working
memory processes to the disrupting effects of the two drugs, or resistance of other factors
involved in the performance of the DNMTP task, cannot be answered based on our study
alone. Further studies are still needed to reveal the exact co-operative role of muscarinic and
NMDA receptors in the regulation of spatial working (short-term) memory performance in
rodents.
6.2.4 Local microinfusion of the NMDA antagonist CPP in the PFC disrupted working
memory dose-dependently.
The blockade of NMDA receptors in the dmPFC dose-dependently disrupted performance in
the DNMTP task. Importantly, CPP 0.1 µg caused a delay-dependent decrease in the
percentage of correct responses, indicating a deficit of working memory function. The
performance was unaffected at the 0 s delay, but was clearly disrupted at the 1 s and 2 s
delays. The delay-dependent effect was mild, since even after vehicle treatment, the
performance of our Wistar rats decreased rapidly close to the chance level, leading to the loss
of significant differences at the longest delays, propably due to the “floor effect”. In addition,
there was also an increase in the percentage of omissions and the latencies of sample press
and nose pokes, suggesting that CPP 0.1 µg caused a mixture of mnemonic and non-
mnemonic (such as attentional) deficits. Earlier studies have shown that a lesion to the rostral
part of the mPFC in rats results in a delay-dependent decrease in task performance, whereas a
lesion in more caudal parts causes a delay-independent performance deficit in the DNMTP
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task (Dunnett, 1990). Our findings support the hypothesis that the rostral part of the dmPFC
has an important role in short-term memory regulation and further suggest the view that
NMDA receptors in the rostral dmPFC are significantly involved in the working memory
processing. Dunnett has suggested that disruption of the mPFC - nucleus accumbens - ventral
pallidum - mediodorsal thalamic nucleus (MD) - mPFC circuit leads to a delay-dependent
SWM deficit in rats (Dunnett, 1990). Since the HC projects both to the ventral pallidum and
mPFC, it is possible that the disruption of this circuit leads to a disconnection between the HC
and the mPFC, which may deteriorate SWM performance. Therefore, a potential mechanism
for NMDA receptor mediated SWM disruption is the functional disturbance of glutamatergic
pathways from the MD (Pirot et al., 1994) or the HC (Gigg et al., 1994) to the mPFC.
The highest CPP dose (0.3 µg) in the dmPFC caused an overall disruption of performance and
a delay-independent decrease in task performance, which cannot be linked primarily to
mnemonic functioning. Since a lesion of the rostral mPFC does not cause a corrsponding
performance deficit, it is possible that the highest dose of CPP may have diffused to more
caudal parts of the mPFC. Lesioning of this area causes a similar kind of delay-independent
deficit. In contrast to our findings after infusing CPP 0.3 µg into the dmPFC, spontaneous
motor activity measured in automated photocell cages was not disrupted after a mPFC lesion
in the study of Dunnett (1990). However, it is difficult to make a direct comparison of the
motor deficits between these two tasks, since they measure different aspects of motor
behaviour. Moreover, the blockade of NMDA receptors specifically modulates only
glutamatergic transmission, and thus its effects cannot be directly compared to the effects of
lesioning.
6.2.5 Local administration of muscarinic antagonist scopolamine in the PFC disrupted non-
mnemonic parametres in the DNMTP task.
In our study, the 10 µg dose of scopolamine was able to induce non-cognitive performance
deficit by increasing the latencies of sample press and nose pokes, but it did not disrupt the
memory performance. Similarly, Dunnett has found that scopolamine 12 µg in the mPFC
caused an overall disruption of performance in the DNMTP task, though, in addition, the
memory performance also decreased delay-independently (Dunnett et al., 1990). However,
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because most of the infusion cannulae in that study were located in the ventromedial PFC, the
effect of different scopolamine doses on DNMTP task performance may have varied in
different subdivisions of the mPFC. In addition, it is also possible that differences  between
the strains of rats used may have affected the results, since Sprague-Dawley rats were used in
that study, whereas we used Wistar rats. On the other hand, Herremans et al. have used Wistar
rats and the placement of the cannulae was near the infusion area of our study (Herremans et
al., 1996). They used the DMTP procedure and found that scopolamine 10 and 30 µg dose-
dependently induced a delay-independent decrease in choice accuracy and disrupted non-
cognitive measures of performance. The present and Herremans et al. study agree that
infusion of scopolamine into the dorsal parts of the mPFC produces non-cognitive deficits.
Therefore, the earlier and present data indicate that muscarinic blockade in the dorsal and
ventral parts of the mPFC primarily results in non-cognitive performance deficits that cause a
delay-independent decrease in task performance. Furthermore, our study showed a clear
difference between the effects of scopolamine and CPP, suggesting that the NMDA and
mACh receptors located in the rostral part of dmPFC mediate different aspects of behaviour
in the DNMTP task.
Previous data suggest that the dlFC is not important for normal spatial working memory.
First, a bilateral lesion of the dlFC causes no disruption of memory performance in the
DNMTP task (Dunnett, 1990). Second, a T -maze study found that a total bilateral lesion of
the dorsolateral isocortex caused only minor disruption of delayed alternation performance,
when compared to the bilateral lesion of the mPFC (Wortwein et al., 1994). Our study did not
show significant effects of scopolamine or CPP on choice accuracy in the DNMTP task when
the drugs were infused into the dlFC. Therefore, our findings contribute to the body of
evidence indicating that the mACh or NMDA receptors in the dlFC do not mediate functions
that are needed for normal spatial working memory per se, as assessed in the DNMTP task.
Moreover, infusion of scopolamine and CPP into the dlFC had different effects on non-
cognitive measures of this task. Scopolamine did not affect non-cognitive performance
measures, whereas CPP 0.3 µg increased the latencies of sample press and nose pokes,
suggesting that a blockade of NMDA receptors, but not muscarinic receptors, in the dlFC
interferes with non-cognitive functioning.
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6.3 SPATIAL LEARNING AND MEMORY
6.3.1 Aging and spatial navigation
The present study showed that after repeated spatial navigation training periods conducted in
the same or different environments, aged rats remained impaired in learning the spatial
navigation task, and were still deficient in their ability to relearn the location of the escape
platform. Furthermore, aged rats were as accurate as young rats in non-spatial navigation
(visible platform), but were still grossly impaired in learning the location of the hidden
platform after non-spatial pre-training in a familiar testing environment. These results indicate
that learning the basic skills of water maze performance during the different pre-training
conditions did not help the aged rats to learn the spatial relationships between the hidden
escape platform and the cues in the testing environment. This is further support for the
concept that the age-related water maze deficit is due to impaired functioning of the septo-
hippocampal system.
Several studies have shown that hippocampal function may be compromised during aging.
Barnes (1994) has reviewed evidence indicating that during normal aging there are regionally
specific deficits in hippocampal synaptic transmission (Barnes, 1994). For example, the
number of synapses from the medial entorhinal cortex to the middle third of the granule cell
dendritic tree is reduced by approximately one-third in aged rats (geinisman et al., 1986) and
this is paralleled by a reduction in the size of the presynaptic fibre potential at stimulus
intensities above threshold (Barnes and McNaughton, 1980b). The aged brain appears to have
a mechanism to compensate for this loss of synapses by making the synapses functionally
more powerfully. The maintenance of synaptic plasticity, as assessed by LTP analysis, is also
impaired in the dentate gyrus of aged rats (Barnes and McNaughton 1980a). Furthermore, the
rate of decay of hippocampal LTP in aged and young rats is inversely correlated with their
learning rates in a spatial memory test (Squire, 1992). Interestingly, previous behavioural
studies have found that lesions of the septo-hippocampal system can also impair spatial
navigation accuracy irrespective of the pre-training protocol. Therefore, our finding that pre-
training did not reverse the spatial navigation deficit in aged rats is compatible with the notion
of HC dysfunction in aged animals.
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6.3.2 Combined administration of THA and DCS at sub-effective doses improves water maze
learning in aged rats, but the improving effect disappears after pre-training.
Our results from the first set of water maze experiments (IV) support previous evidence that
administration of THA and DCS before daily training sessions can improve acquisition of
spatial navigation in aged rats (Riekkinen et al., 1996; Riekkinen and Riekkinen, 1997).
Importantly, a combination of sub-threshold doses of THA and DCS produced a greater effect
on water maze acquisition and spatial search bias than either of the treatments on their own.
However, THA and DCS had no effect on memory consolidation, as treatment with the study
drugs immediately after daily training did not improve spatial escape behaviour. The second
set of experiments (V) revealed that any kind of pre-training, either non-spatial or spatial, was
able to block the beneficial effects of THA and DCS, administered either separately or in
combination. Furthermore, THA and DCS had no effect on age-related impairment of reversal
learning. When compared to the young controls, the spatial learning deficit of aged rats still
remained after either spatial or non-spatial pre-training.
In the first set of water maze experiments (IV), the number of rats that found the platform on
the first trial of the first day was not affected by the drug treatments. This suggests that the
compounds do not change the spontaneous exploration patterns of rats, and may also rule out
effects on anxiety. However, the beneficial action of THA and DCS on water maze escape
performance during the hidden platform trials cannot be interpreted solely in terms of
enhanced spatial memory. It is possible that changes in arousal and attention may affect water
maze acquisition if the drugs are administered before daily training sessions. For example, the
learning curves of rats treated with THA and DCS were parallel, which may be a reflection of
some non-mnemonic improvement in performance. In addition, THA alone had no effect on
the spatial bias measure, suggesting that the encoding of spatial cues was not improved by
THA. Importantly, in the second set of experiments (V), THA lost its navigation improving
effect after non-spatial pre-training. Thus, it is likely that THA treatment stimulates
acquisition of spatial navigation by modulating some process other than spatial memory per
se. The NBM cholinergic system modulates the functioning of the frontal cortex and plays an
important role in attention (Jäkälä et al., 1992; Muir et al., 1994; Muir et al., 1995). Lesions of
the NBM induced by infusion of excitatory amino acid analogues or treatment with a mACh
receptor antagonist impair behaviour in young rats in tests measuring attention (Jäkälä et al.,
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1992; Muir et al., 1994; Muir et al., 1995). Therefore, it is possible that improved attention in
the aged rats induced by THA treatment may contribute to the facilitated water maze
acquisition.
We observed that DCS enhanced spatial bias during the memory retrieval trial, suggesting
that the drug may stimulate spatial memory function. However, a study by Bannerman et al.
suggests that NMDA receptors mediate functions other than spatial memory, such as the
development of an escape strategy, that are important for water maze spatial navigation
(Bannerman et al., 1995). Furthermore, we observed that the learning curves of aged rats
treated with DCS or a placebo before daily training sessions were parallel, and DCS failed to
stimulate memory consolidation. Therefore, it is possible that DCS does not specifically
stimulate spatial memory in aged rats, but modulates other cognitive processes needed for
effective spatial navigation (Bannerman et al., 1995). Findings from our second set of
experiments support this since, as in the case of THA, the improving effect of DCS vanished,
despite a variety of different types of (including non-spatial) pre-training (V). Taken together,
the results from our experiments suggest that both DCS and THA facilitate other cognitive
components of water maze learning than spatial memory per se.
Our studies showed that a cholinesterase inhibitor and a NMDA modulator jointly improved
acquisition in the water maze task, since we found that a combination of THA and DCS at
sub-threshold doses decreased escape distance and increased spatial bias. In contrast, a
combination of active THA and DCS doses did not produce any greater effect on acquisition
or retention of water maze behaviour than did either of the treatments alone. These results
indicate that THA and DCS may act synergistically to enhance functioning of the brain
systems necessary for water maze acquisition, but only DCS stimulated those mechanisms
important for retrieval of spatial memories. Importantly, it has been shown that treatment with
the cholinesterase inhibitor physostigmine can increase functioning of glutamate containing
projection neurons (Dijk et al., 1995). These workers used ‘in vivo’ microdialysis to show
that glutamate release from corticostriatal fibres was enhanced by cholinesterase inhibition.
Thus, it is possible that the increase in ACh activity occurring after THA treatment can
stimulate water maze performance by enhancing glutamate mediated functions. Therefore,
sub-threshold doses of THA and DCS may produce a measurable effect on water maze
navigation by stimulating glutamate release and NMDA receptor activity, respectively (Dijk
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et al., 1995; Huettner, 1991).
An additional possible mechanism for increasing ACh activity to improve water maze
navigation is the stimulation of nicotinic receptors. We have observed in our laboratory that
subthreshold doses of nicotine and DCS dose-dependently improved spatial navigation in
aged rats (Riekkinen and Riekkinen, 1997). We also found that DCS alleviated the water
maze acquisition defect induced by a nicotinic antagonist, and a subthreshold dose of the
NMDA antagonist CPP blocked the beneficial effect of nicotine on water maze acquisition
(Riekkinen and Riekkinen, 1997). Therefore, it is possible that activation of nicotinic ACh
receptors may stimulate water maze acquisition in aged rats via increased activity of NMDA
receptors and also partially mediate the simulating effects of THA. Indeed, THA can activate
niconinic receptors through an allosteric binding site (Paterson and Nordberg, 2000).
However, further studies are still needed to specify the relationship between muscarinic and
nicotinic receptor activation in the regulation of age-related cognitive decline in rodents.
The present results may have some relevance for the development of pharmacological
treatments for cognitive defects observed in AD that are associated with impaired functioning
of NMDA and basal forebrain cholinergic systems (Aigner, 1995; Francis et al., 1999;
Whitehouse et al., 1982). It is possible that combined treatment with a cholinesterase inhibitor
and a positive NMDA modulator may produce a clinical response with lower doses than
either treatment alone, which would also decrease dose-dependent side effects. Furthermore,
drugs acting via different neurochemical systems may enhance separate cognitive domains,
such as memory or attention, although combined treatment with a cholinesterase inhibitor and
a positive allosteric modulator of NMDA receptors probably does not directly stimulate
memory functions. However, the drugs likely have indirect beneficial effects on cognition.
Our results suggest that a combination of these drugs may interact in alleviating cognitive
deficits and clinical dementia in AD. Unfortunately, DCS can only be considered an
experimental molecule, suitable for evaluating the possible therapeutic actions of drugs acting
via NMDA receptors, as efficacy in human studies has been dissapointing (Laake and
Oeksengaard, 2002). Nevertheless, our data support the development of new compounds
targeted to enhance NMDA receptor activity.
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7. CONCLUSIONS
1. Antagonism of NMDA and muscarinic M1 (+ M3 + M4) acetycholine receptors impaired
performance in the DNMTP task, a typical working memory task.
Because the effect was largely delay-independent and observed in non-mnemonic task
parameters, it is likely to be mediated by non-mnemonic aspects of the task, and not by
specific disruption of working memory processes. Instead, M2 antagonists at a low dose
may block presynaptic autoreceptors and thus stimulate cholinergic function.
2. The non-specific effects of muscarinic and NMDA receptor blockade were even more
pronounced, when a combination of muscarinic ACh and NMDA receptor antagonists
was administered.
3. At the prefrontal cortex level, the antagonism of NMDA receptors has different effect
profile when compared to the muscarinic receptor antagonism. NMDA receptors mediate
processes that are needed for working memory regulation, whereas muscarinic receptors
regulate non-mnemonic aspects of the DNMTP task.
4. Stimulation of cholinergic system and NMDA receptors interact in enhancing procedural
aspects of water maze navigation learning, which is reflected as an alleviation of the age-
related spatial navigation deficit in rats.
5. Although the conjoint modulation of muscarinic and NMDA receptors probably does not
directly enhance memory functions, the indirect effects on learning possibly due to
stimulation of attentional or other non-mnemonic processes might help to treat the
cognitive symptoms of patients suffering from age-related neurodegenerative diseases,
such as AD.
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